

# BMJ Open

## Prevalence, Associated Factors and the Heritability of Metabolic Syndrome and its Individual Components in African American: The Jackson Heart Study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2015-008675
Article Type:	Research
Date Submitted by the Author:	04-May-2015
Complete List of Authors:	Khan, Rumana; National Institutes of Health, National Human Genome Research Institute Gebreab, Samson; National Institutes of Health, National Human Genome Research Institute Sims, Mario; University of Mississippi Medical Center, Department of Internal Medicine Crespo, Pia; National Institutes of Health, National Human Genome Research Institute Xu, Ruihua; National Institutes of Health, National Human Genome Research Institute Davis, Sharon; National Institutes of Health, National Human Genome Research Institute
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Public health
Keywords:	Hypertension < CARDIOLOGY, EPIDEMIOLOGY, Diabetes & endocrinology < INTERNAL MEDICINE

SCHOLARONE™  
Manuscripts

**Title page:**

**Title: Prevalence, Associated Factors and the Heritability of Metabolic Syndrome and its Individual Components in African American: The Jackson Heart Study**

**Corresponding author:**

Rumana J Khan

Cardiovascular Section

Genomics of Metabolic, Cardiovascular and Inflammatory Disease Branch, Social Epidemiology

Research Unit, National Human Genome Research Institute, 10 Center Drive, Room 7N316

MSC 1644, Bethesda, MD 20892

e-mail address: rumana.khan@nih.gov

Main: 301-451-2447

Direct: 301-451-2127

Fax: 301-480-0063

**Author names and affiliations****Rumana J Khan, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,

National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,

USA.

**Samson Y Gebreab, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,  
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,  
USA.

**Mario Sims, PhD**

Division of Hypertension, Department of Internal Medicine, University of Mississippi Medical  
Center, Jackson, Mississippi, USA

**Pia R Crespo, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,  
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,  
USA.

**Ruihua Xu, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,  
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,  
USA.

**Sharon K Davis, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,  
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,  
USA.

**Keywords:** Metabolic Syndrome, African Americans, Heritability, Associated factors

**Word count:**

The total word count of text: 2965

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Background:** Both environmental and genetic factors play important roles in development of metabolic syndrome (MetS). Studies about its associated factors and genetic contribution in African Americans (AA) are sparse. Our aim was to report the prevalence, associated factors and heritability estimates of MetS and its components in AA.

**Methods:** This is a cross-sectional analysis of data of 5227 individuals from the Jackson Heart Study. Multiple logistic regression analysis was used to isolate independently associated factors of MetS. Heritability was estimated from the family study subset (1636 individuals, 281 families) using variance component methods.

**Results:** 27% of men and 40% of women had MetS. For men, associated factors with having MetS were older age, lower physical activity, higher body mass index, higher homocysteine and adiponectin level ( $p < 0.05$  for all). For women, in addition, lower education, current smoking, and higher stress were also significant ( $p < 0.05$  for all). Heritability of MetS was 32% ( $p < 0.01$ ), and ranged from 14 to 45% for its five components. Relatively higher heritability was estimated for waist circumference (45%), high density lipoprotein-cholesterol (43%) and triglycerides (42%). Heritability for systolic blood pressure (BP), diastolic BP, and fasting blood glucose were 16%, 15%, and 14%, respectively.

**Conclusion:** Stress and low education were associated with having MetS in AA women, but not in men. Higher heritability estimates for lipids and waist circumference supports the hypothesis of lipid metabolism playing the central role in the development of MetS and encourages additional efforts to identify the underlying susceptibility genes for this syndrome in AA.

## Strengths and limitations of this study

- African American community disproportionately suffers from metabolic syndrome, but relatively little is known about the genetic contribution and the environmental influence of this syndrome among African Americans.
- Using the data from large, community-based Jackson Heart study, this study showed a high prevalence of metabolic syndrome, and reported the associated factors and heritability estimates of metabolic syndrome and its components in African Americans.
- We are not aware of any published data that explored these issues among African American from such a big setting. The large sample size also provided a reliable statistical ground to detect heritability estimates than nuclear families, twin pair data or sib-pair data.
- Potential limitations of this study included the cross-sectional observational design, which could only confirm the associations of the factors with metabolic syndrome, but not the causality, and the absence of information on shared environmental factors like childhood environment and neighborhood factors, which might slightly overestimated the heritability results.
- This study encourages additional efforts to identify the underlying susceptibility genes for metabolic syndrome among African Americans.

## BACKGROUND

Metabolic syndrome (MetS) is a clustering of different interrelated cardio-metabolic risk factors including obesity, elevated blood pressure (BP), dyslipidemia, and impaired fasting plasma glucose (IFG). These risk factors often occur together and increases cardiovascular disease (CVD) deaths almost by three to four fold.<sup>1,2</sup> As MetS is the combined effect of more than one risk factor, the etiology of the MetS is complex. Factors like lifestyle, gender, ethnicity, socioeconomic status, psychosocial factors and some inflammatory markers play key roles in the pathogenesis of MetS.<sup>1-3</sup> Findings also suggest that MetS clusters in families<sup>4-8</sup> and has reasonable heritability, which is defined as the proportion of phenotypic variance in a trait that is attributable to the additive effects of genes.<sup>9-17</sup> Thus, the interplay of both environmental and genetic factors makes MetS a multifactorial disorder.

Though the pathogenesis, diagnosis and the treatment of MetS remain complex because of its multifactorial nature, the construct MetS is an important risk-assessment method for early detection and early intervention of CVD. In spite of steady decline in CVD mortality during recent decades, CVD is still the leading cause of death in all Americans, and is highly prevalent in persons of African ancestry.<sup>18</sup> It is important to note that the majority of studies that explored the associated factors and quantified the heritability of MetS almost exclusively involved Caucasians.<sup>10-14, 19</sup> Relatively little is known about these issues among adult African American (AA) population.<sup>15-17</sup> Using the Jackson Heart Study (JHS) data, this cross-sectional study reports the prevalence, risk factors and heritability estimates MetS and its components in AA.

## METHODS

### Data Source

Data of this analysis comes from large and community based JHS, which comprises 5301 adult AA enrolled between September 2000 and March 2004 residing in Jackson, Mississippi, metropolitan area.<sup>20</sup> About 24% of 5301 participated in the JHS family study component.<sup>21</sup> The JHS was approved by the University of Mississippi Medical Center Institutional Review Board, and the participants gave written informed consent. Details of the study design and data collection methods are described elsewhere.<sup>21,22</sup> After excluding 74 participants who didn't have information on their MetS status, the current analysis had a total of 5227 participants, of which 1636 from 281 families contributed to the heritability analyses.

### Measures

We collected information on participant's waist circumference (WC), systolic BP (SBP) and diastolic BP (DBP), fasting blood glucose (FPG), fasting triglyceride, and plasma high-density lipoprotein cholesterol (HDL-C). Two measures of the waist at the level of the umbilicus and in the upright position were averaged to calculate WC. Sitting BP was measured twice at 5-min intervals, and the average of two measurements was used. Fasting blood samples were collected according to standardized protocols, and the assessments of FPG and lipids were processed at the Central Laboratory, University of Minnesota.<sup>23</sup> Individuals were classified as having MetS if they had at least three of the following five components: (1) large WC or abdominal obesity ( $> 102$  cm for men and  $> 88$  cm for women); (2) hypertriglyceridemia (fasting plasma triglyceride concentration  $\geq 150$  mg/dL or on drug treatment); (3) low HDL-C levels ( $< 40$  mg/dL for men and  $< 50$  mg/dL in women or on drug treatment); (4) elevated BP



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

( $\geq 130$  mm Hg SBP or  $\geq 85$  mm Hg DBP or on drug treatment); or, (5) IFG ( $\geq 110$  mg/dL or on drug treatment).<sup>24, 25</sup>

Data about socio-demographic (age, sex, and education); the psychosocial (stress) and lifestyle (physical activity, smoking status, and alcohol consumption) variables were also collected. Age was classified as: 20-39, 40-59, 60-79 and 80 years and above. Education status was self-reported and was divided into three categories (less than high school being the referent). Stress level was obtained from The Global Perceived Stress Scale, which is an 8-item questionnaire that measures the severity of chronic stress experienced over a prior period of twelve months.<sup>26</sup> The physical activity index composite score was calculated as the sum of four different domains of physical activity: active living, work, home and garden, and sport and exercise indexes.<sup>27</sup> Smoking status was classified as never (referent), current, and former. Alcohol consumption status was defined as “yes” if they currently consumed alcoholic beverages and “no” (referent) if they had stopped drinking more than a year back, or if they never consumed alcohol. Information on clinical factors like body mass index or BMI (weight in kg divided by height in meter square), C reactive protein or CRP (mg/dL), serum adiponectin (mg/dL), and serum homocysteine (umol/L) were also obtained.<sup>23</sup>

## Analysis

Data from the full cohort (n= 5227) were used to explore the risk factors of MetS. Socio-demographic, psychosocial, lifestyle and clinical characteristics of participants were compared by gender and MetS status using the chi-square or independent t test. The primary outcome measure for this analysis was the presence of MetS, evaluated as a dichotomous variable.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Logistic regression analysis was used to examine the association between each independent variable (age, education level, stress level, physical activity score, smoking status, alcohol consumption status, BMI, CRP, fasting total cholesterol, serum concentration of adiponectin, and serum homocysteine) with the outcome of MetS. A multiple logistic regression model was fitted including all variables to isolate the statistically significant predictors of MetS.

### Heritability Analysis

After checking the pedigree data for inconsistencies a total of 1636 individuals from 281 families were analyzed to calculate the heritabilities by variance component methods using SOLAR (Sequential Oligogenic Linkage Analysis Routines) software.<sup>28</sup> We estimated the heritability of individual MetS components including WC, SBP, DBP, FPG, fasting triglyceride, and plasma HDL-C with adjustment for age, education level, physical activity index composite score, smoking status, alcohol consumption status and respective medication usage. Log transformed values of FPG and triglycerides were used due to deviation from normal distribution. Heritabilities were calculated using a standard quantitative genetic variance-components model implemented in SOLAR.<sup>28</sup> This approach uses the maximum-likelihood estimation to a mixed-effects model that incorporates fixed covariate effects, additive genetic effects and residual error. The heritability of MetS (discrete variable) was analyzed by a threshold model in SOLAR. The method assumed that an individual belonged to a specific affected status if an underlying genetically determined risk exceeded a certain threshold.<sup>29</sup>

## RESULTS

Out of 5227 individuals, 1909 (36.52%, mean age 53.93 years and standard deviation or SD=12.93) were men and 3318 (63.48%, mean age 55.30 years and SD=12.76) were women.

According to characteristics presented in table 1, education level were similar for men and women. About 40% of men and women had college level education or beyond. A clear gender difference however, was found in alcohol use and smoking, with women being far less likely than men to consume alcohol and smoke cigarettes ( $p<0.001$ ). Women reported greater levels of stress, but lower level of physical activity than men ( $p<0.001$ ). Women also had higher BMI, CRP, adiponectin, and lower homocysteine level than men ( $p<0.001$  for all). Table 1 also shows the prevalence of MetS and its individual components among the JHS participants. About 27.34% of the men and 38.94% of the women had MetS ( $p<0.001$ ). In terms of individual components, women had higher abdominal obesity (75.70% versus 41.03%,  $p<0.001$ ) and IFG (22.45% versus 19.64%,  $p<0.001$ ), but lower hypertriglyceridemia (13.23% versus 18.39%,  $p<0.001$ ) than men.

**Table 1: Characteristics of the 1909 male and 3318 female participants of the Jackson Heart Study (N=5227)**

	<b>Men<sup>a</sup> n=1909</b>	<b>Women<sup>a</sup> n=3318</b>	<b>P value<sup>b</sup></b>
<b>Age in years</b>	53.93 (12.93)	55.30 (12.76)	0.0002
<b>Education level</b>			
Less than high school	18.73	17.88	
High school/GED or some college	42.82	41.83	
College/associate degree or higher	38.45	40.29	0.4094
<b>Smoking Status</b>			
Never	56.68	74.59	
Former	25.33	15.30	
Current	17.99	10.11	<.0001
<b>Alcohol drinking status</b>			
Yes	58.92	38.41	
No	41.08	61.59	<.0001
<b>Total Physical Activity Score<sup>c</sup></b>	8.64 (2.63)	8.16 (2.58)	<.0001
<b>Global Stress Total Score<sup>d</sup></b>	4.50 (4.20)	5.52 (4.45)	<.0001
<b>Body mass index (weight in kg/height in squared meter)</b>	29.83±6.14	32.86 (7.59)	<.0001
<b>High Sensitivity C-Reactive Protein in mg/dL</b>	0.35 (0.96)	0.60 (0.85)	<.0001
<b>Homocysteine in umol/L</b>	10.17 (3.56)	9.00 (5.20)	<.0001
<b>Adiponectin level in µg/mL</b>	4.15 (3.41)	6.15 (4.57)	<.0001
<b>Abdominal obesity<sup>e</sup></b>	41.03	75.70	<.0001
<b>Hypertriglyceridemia</b>	18.39	13.23	<.0001
<b>Low HDL-C<sup>g</sup></b>	33.01	39.55	<.0001
<b>Elevated blood Pressure<sup>h</sup></b>	69.62	70.58	0.4616
<b>impaired fasting glucose<sup>i</sup></b>	19.64	22.45	0.0171
<b>Metabolic syndrome<sup>k</sup></b>	27.34	38.94	<.0001

<sup>a</sup>Data presented as mean (SD) or percentage of subjects

<sup>b</sup>Independent t test or Chi-square test;

<sup>c</sup>sum of the four different domains of physical activity;

<sup>d</sup>sum of 8 item questionnaire that measures the severity of chronic stress experienced over a prior period of twelve months;

<sup>e</sup>waist circumference > 102 cm for men and > 88 cm for women

<sup>f</sup>fasting plasma triglyceride concentration ≥ 150 mg/dL or on drug treatment

<sup>g</sup>HDL cholesterol levels <40 mg/dL for men and < 50 mg/dL in women or on drug treatment

<sup>h</sup>Blood pressure ≥ 130 mm Hg systolic or ≥ 85 mm Hg diastolic or on drug treatment

<sup>i</sup>fasting glucose ≥ 110 mg/dL or on drug treatment

<sup>k</sup>Metabolic Syndrome defined as having at least three of the following five components: (1) abdominal obesity; (2) hypertriglyceridemia; (3) low HDL cholesterol levels; (4) elevated blood; (5) impaired fasting glucose

1  
2  
3 Table 2 shows the descriptive characteristics of participants by MetS status. Those who had  
4 MetS were older, less educated, less likely to smoke, less likely to consume alcohol, and less  
5 physically active ( $p < 0.001$  for all). They also had higher BMI, higher CRP and higher  
6 homocysteine level; but lower adiponectin concentration ( $p < 0.001$  for all). The unadjusted and  
7 the adjusted relationships of MetS with these features are displayed in table 3. After  
8 adjustment, older age remained significant for both men and women. Notably, the trend of  
9 having MetS with increasing age was clearer for women than for men. Education was only  
10 significant for women, and not for men. Women who went to high school had 24% (adjusted  
11 odds ratio or AOR: 0.76; 95% confidence interval or CI: 0.59-0.97) decreased odds of having  
12 MetS compared to those who had the lowest education level. Like education, higher stress level  
13 was also a significant factor for women only (AOR: 1.02; 95% CI: 1.01-1.04). Physical activity  
14 decreased the odds of having MetS for both sexes, but alcohol consumption was associated  
15 with 26% decreased odds (AOR: 0.74; 95% CI: 0.61-0.90) of MetS for women only.  
16  
17 Relationship between smoking and MetS was different for men and women. While current  
18 smoking only predicted women's MetS (AOR: 1.43; 95% CI: 1.07-1.91), former smoking had  
19 significant association with men's MetS (AOR: 1.54 ; 95% CI: 1.14-2.08). Biomedical risk  
20 factors such as increased BMI (AOR: 1.18; 95% CI: 1.15-1.21 for men and AOR: 1.08; 95%  
21 CI: 1.07-1.10 for women), increased serum homocysteine (AOR: 1.05; 95% CI: 1.02-1.09 for  
22 men and AOR: 1.06; 95% CI: 1.03-1.09 for women) and decreased serum adiponectin  
23 (AOR: 0.90; 95% CI: 0.85-0.95 for men and AOR: 0.90; 95% CI: 0.87-0.92 for women) were  
24 associated with increased odds of having MetS for both sexes.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2: Characteristics of Jackson Heart Study Participants by metabolic syndrome status (N=5227)**

	<b>Metabolic Syndrome<sup>a</sup> (n=1814)</b>	<b>No Metabolic Syndrome<sup>a</sup> (n=3413)</b>	<b>P value<sup>b</sup></b>
<b>Age in years</b>	58.04 (11.43)	53.07 (13.21)	<.0001
<b>Gender of Participant</b>			
Men	28.78	40.46	
Women	71.22	59.36	<.0001
<b>Education level</b>			
Less than high school	23.32	15.46	
High school/GED or some college	41.94	42.33	
College/associate degree or higher	34.74	42.21	<.0001
<b>Smoking Status</b>			
Never	66.17	69.05	
Former	21.59	17.56	
Current	12.24	13.39	0.0017
<b>Alcohol drinking status</b>			
Yes	37.01	50.63	
No	62.99	49.37	<.0001
<b>Total Physical Activity Score<sup>c</sup></b>	7.74 (2.56)	8.65 (2.57)	<.0001
<b>Global Stress Total Score<sup>d</sup></b>	5.11 (4.42)	5.17 (4.37)	0.6251
<b>Body mass index (weight in kg/height in squared meter)</b>	34.87 (6.92)	30.10 (6.86)	<.0001
<b>High Sensitivity C-Reactive Protein in mg/dL</b>	0.65 (1.13 )	0.44 (0.74)	<.0001
<b>Homocysteine: The concentration of homocysteine in umol/L</b>	9.94 (6.37)	9.15 (3.44)	<.0001
<b>Serum concentration of adiponectin in µg/mL</b>	4.72 (4.02)	5.79 (4.38)	<.0001

<sup>a</sup>Data presented as mean (SD) or percentage of subjects

<sup>b</sup>Independent t test or Chi-square test;

<sup>c</sup>sum of the four different domains of physical activity;

<sup>d</sup>sum of 8 item questionnaire that measures the severity of chronic stress experienced over a prior period of twelve months;

**Table 3: Association between selected factors and prevalence of metabolic Syndrome among Jackson Heart Study Participants (n=5227)**

	Metabolic Syndrome Odds Ratio (95% CI)			
	Men (n=1909)		Women (n=3318)	
	Unadjusted <sup>a</sup>	Adjusted <sup>a</sup>	Unadjusted <sup>a</sup>	Adjusted <sup>a</sup>
<b>Age</b>				
20-39 (Ref)	1		1	
40-59	1.34(0.96-1.86)	1.55 (1.02-2.35)	2.44(1.84-3.23)	2.79 (2.00 -3.87)
60-79	1.69(1.20-2.38)	2.17 (1.34-3.51)	4.69(3.54-6.22)	5.50 (3.81-7.93)
80 and above	0.88(0.28-2.71)	2.18 (0.60-8.00)	3.43(1.89-6.24)	5.06 (2.34-10.96)
<b>Education</b>				
Less than High school	1		1	
High school or some College	0.95(0.72-1.25)	1.20 (0.83-1.74)	0.53(0.44-0.65)	0.76 (0.59- 0.97)
College degree or higher	0.79(0.60-1.05)	1.05 (0.72 1.55)	0.44(0.36-0.53)	0.82 (0.63-1.07)
<b>Smoking Status</b>				
Never	1		1	
Former	1.47(1.16-1.85)	1.54 (1.14-2.08)	1.39(1.15-1.69)	1.20 (0.95-1.52)
Current	0.92(0.69-1.22)	1.29 (0.89-1.86)	1.20(0.95-1.51)	1.43 (1.07-1.91)
<b>Alcohol drinking</b>				
No	1		1	
Yes	0.72(0.59-0.88)	0.85 (0.66-1.11)	0.57(0.49-0.66)	0.74 (0.61-0.90)
<b>Physical Activity<sup>b</sup></b>	0.90(0.86-0.94)	0.93 (0.88- 0.98)	0.86(0.84-0.89)	0.94 (0.91-0.98)
<b>Global Stress<sup>c</sup></b>	1.01(0.98-1.03)	1.02 (0.99-1.06)	0.98(0.97-1.00)	1.02 (1.01- 1.04)
<b>Body mass index</b>	1.18(1.15-1.20)	1.18 (1.15-1.21)	1.08(1.07-1.09)	1.08 (1.07-1.10)
<b>C-Reactive Protein in mg/dL</b>	1.36(1.15-1.60)	1.10 (0.96- 1.26)	1.29(1.18-1.41)	0.99 (0.89-1.09)
<b>Homocysteine in umol/L</b>	1.04(1.01-1.07)	1.05 (1.02 1.09)	1.07(1.05-1.10)	1.06(1.03-1.09)
<b>Adiponectin in µg/mL</b>	0.89(0.85-0.92)	0.90 (0.85-0.95)	0.91(0.90-0.93)	0.90 (0.87-0.92)

Metabolic Syndrome defined as having at least three of the following five components: (1) abdominal obesity or large waist circumference (> 102 cm for men and > 88 cm for women); (2) hypertriglyceridemia (fasting plasma triglyceride concentration  $\geq$  150 mg/dL or on drug treatment); (3) low HDL cholesterol levels (< 40 mg/dL for men and < 50 mg/dL in women or on drug treatment); (4) elevated blood pressure ( $\geq$  130 mm Hg systolic or  $\geq$  85 mm Hg diastolic or on drug treatment); or, (5) IFG or impaired fasting glucose (110 mg/dL or on drug treatment)

<sup>a</sup>Analysis done using simple and multiple logistic regression. The multivariate models are adjusted for for all other variables in the table.

<sup>b</sup>sum of the four different domains of physical activity;

<sup>c</sup>sum of 8 item questionnaire that measures the severity of chronic stress experienced over a prior period of twelve months;

1  
2  
3  
4  
5  
6 Table 4 illustrates the heritability estimates along with the proportion of variation explained by  
7  
8 covariates ( $\sigma_e^2$ ) of MetS and its individual component in the family study subset (n=1636). All  
9  
10 components of the MetS were significantly correlated with each other except for the pairs of  
11  
12 blood pressure and HDL-C and blood pressure and fasting glucose (results not shown in table).  
13  
14 After accounting for the covariates (except medication), the heritability of MetS was about 32%  
15  
16 ( $p<0.0001$ ,  $\sigma_e^2$ : 10%). The adjusted heritability of individual MetS components ranged from the  
17  
18 lowest of 14% ( $p<0.01$ ,  $\sigma_e^2$ : 33%) for FPG to the highest of 45% ( $p<0.0001$ ,  $\sigma_e^2$ : 8%) for WC  
19  
20 after adjusting for all the covariates. The adjusted estimates of DBP (15%,  $p<0.01$ ,  $\sigma_e^2$ : 9%) and  
21  
22 SBP (16%,  $p<0.001$ ,  $\sigma_e^2$ : 22%) were on the lower end and similar to the estimate of FPG.  
23  
24 Conversely, heritability of triglyceride (42%,  $p<0.001$ ,  $\sigma_e^2$ : 10%) and HDL-C (43%,  $p<0.001$ ,  
25  
26  $\sigma_e^2$ : 11%) was relatively high and similar to the heritability of WC.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 4: Heritability estimates of Metabolic Syndrome and its individual components of Jackson Heart Study Participants (n=1636)**

	Heritability Estimate	Standard error	P value	Variations explained by covariate
<b>Metabolic Syndrome<sup>a</sup></b>	0.32	0.08	<0.0001	0.10 <sup>e</sup>
<b>Fasting Plasma Glucose<sup>b,c</sup></b>	0.14	0.06	<0.01	0.33 <sup>d</sup>
<b>Waist Circumference<sup>b</sup></b>	0.45	0.06	<0.0001	0.08 <sup>e</sup>
<b>High Density Lipoprotein Cholesterol<sup>b</sup></b>	0.43	0.07	<0.0001	0.11 <sup>d</sup>
<b>Fasting Triglyceride<sup>b,c</sup></b>	0.42	0.05	<0.0001	0.10 <sup>d</sup>
<b>Systolic blood pressure<sup>b</sup></b>	0.16	0.07	<0.001	0.22 <sup>d</sup>
<b>Diastolic blood pressure<sup>b</sup></b>	0.15	0.05	<0.01	0.09 <sup>d</sup>

<sup>a</sup>Treated as discrete trait, and defined as having at least three of the following five components: (1) abdominal obesity or large waist circumference (> 102 cm for men and > 88 cm for women); (2) hypertriglyceridemia (fasting plasma triglyceride concentration  $\geq$  150 mg/dL or on drug treatment); (3) low HDL cholesterol levels (< 40 mg/dL for men and < 50 mg/dL in women or on drug treatment); (4) elevated blood pressure ( $\geq$  130 mm Hg systolic or  $\geq$  85 mm Hg diastolic or on drug treatment); or, (5) IFG or impaired fasting glucose (110 mg/dL or on drug treatment)

<sup>b</sup>Treated as continuous trait

<sup>c</sup>Log transformed

<sup>d</sup> Covariates are age, sex, education, smoking status, alcohol intake, physical activity and respective medication

<sup>e</sup> Covariates are age, sex, education, smoking status, alcohol intake, physical activity

## DISCUSSION

Overall, in our study sample, the prevalence of MetS was higher among women than men.

Factors independently associated with having MetS for men were older age, lower physical activity level, higher BMI, higher level of homocysteine and lower level of adiponectin. For women, in addition to these factors, low education, higher stress, current smoking and alcohol consumption were also significant. The heritability of the MetS was 32% and among its individual components, heritability ranged from 14% for FPG to 45% for WC.

1  
2  
3 The prevalence of MetS that we found (38.94% of women and 27.34% of men) was almost  
4  
5 identical to a recent estimate from a National Survey, which reported 38.2% of AA women and  
6  
7 25.5% of AA men had MetS.<sup>1</sup> A higher prevalence of MetS in women than in men has been  
8  
9 reported in several other Asian and Eastern European countries, as well as among Hispanic, and  
10  
11 Native Americans.<sup>1, 30-32</sup> However, it is opposite for US Caucasians with higher prevalence in  
12  
13 men.<sup>1</sup> This, together with our finding suggest the possibility of an increased risk of MetS for  
14  
15 women belonging to an economically disadvantaged or a minority population group. The  
16  
17 unfavorable condition of women was also evident from our multivariate analysis, where we  
18  
19 found lower education and stress to be significantly related with MetS for women, but not for  
20  
21 men. While in the industrialized society social class and education are typically inversely  
22  
23 related to different cardio-metabolic risk factors regardless of gender,<sup>33-35</sup> in our study, this was  
24  
25 true only for women, indicating an adverse social environment of our women participants.  
26  
27 Literature have indicated active smoking to be associated with development of MetS.<sup>36, 37</sup> We  
28  
29 however found, active smoking to be associated with women's MetS only. The lack of  
30  
31 association between current smoking and MetS among men in our study can be partly attributed  
32  
33 to the much discussed inverse association between active smoking and obesity as the smoking  
34  
35 prevalence was higher and abdominal obesity was relatively lower in the men than women in  
36  
37 our analysis.<sup>38</sup> Further, researchers have also found smoking cessation to be frequently  
38  
39 followed by weight gain,<sup>39</sup> which explains our observed association between past smoking and  
40  
41 men's MetS.  
42  
43  
44  
45  
46  
47  
48  
49

50 Although lifestyle, physiological and socio-demographic factors play key roles in the  
51  
52 pathogenesis of MetS, there is also strong evidence that the syndrome is inherited.<sup>40-43</sup> We  
53  
54 evaluated the contributions of genetic factors to the phenotypic variability of MetS and its traits  
55  
56  
57  
58  
59  
60

1  
2  
3 by heritability estimation. According to various studies from different ethnic groups,  
4 heritability of MetS ranges from approximately 19 to 38%.<sup>10-13</sup> Besides the genetic effect itself,  
5 which could be different among different studied populations, the discrepancy in heritability  
6 might be attributable to other factors like different sample sizes, different structure of pedigrees  
7 or covariates included in the analysis. A Dutch study estimated a heritability of 19.2% of MetS  
8 in an isolated group of population.<sup>11</sup> A heritability of 24% in a Caribbean-Hispanic population  
9 has been reported by Lin et al.<sup>12</sup> The heritability for the Caucasian population was about 27%  
10 according to large population based study.<sup>10</sup> Bayoumi et al. reported a heritability of 38% of  
11 MetS in healthy Omani Arab families.<sup>13</sup> Compared to different ethnic groups, relatively little  
12 information is available on the heritability of MetS in AA population. The heritability of MetS  
13 in our study was 32% after taking into account the contributions of covariates, like age, sex,  
14 alcohol consumption, smoking and physical activity level, suggesting that more than one-third  
15 of the variance in MetS was attributable to the additive effects of genes in the JHS participants.  
16 This estimate is on the higher end of the heritability range reported so far, which suggests  
17 significant genetic influences on clustering of risk factors among AA.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 Reported heritability from different studies for the individual traits ranges from 10% for plasma  
42 glucose to 60% for HDL-C.<sup>10-14, 19</sup> Our estimates correspond well with these findings. In the  
43 present study, more than 40% of the variance in HDL-C, triglyceride and WC was attributable  
44 to genetic effect. Conversely, a moderate but significant heritability were observed for BP and  
45 FPG. In different studies as well, HDL-C, obesity and lipid profiles showed the strongest  
46 heritability, and BP and FPG had the lowest heritability.<sup>10-14</sup> While for lipid levels and WC  
47 genetic influence remains dominant; it seems, for FPG and BP the environmental contribution  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 play a more prominent role, which was apparent by the remarkable covariate effect that was  
4 observed for FPG and BP (33% and 22%, respectively) not only in our findings, but also in  
5 some other studies.<sup>10, 12</sup> This hypothesis is further supported by some genetic association  
6 studies, where investigators have tried to find a unifying pathogenic mechanism for the  
7 different MetS components and identify genetic variants contributing to MetS. No such work  
8 among AA were found, but a meta-analysis of 4000 Asian and Caucasian participants  
9 reviewing 25 genes reported an association between MetS and single nucleotide  
10 polymorphisms in the FTO, TCFL72, IL6, APOA5, APOC3 and CETP genes.<sup>44</sup> Another  
11 Swedish study found that genetic variants in the PPARG and ADRB1 genes conferred an  
12 increased risk of future MetS<sup>45</sup>. All of these genes are mostly involved in lipid metabolism<sup>44,</sup>  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

These evidence indicate that lipid metabolism plays the central role in MetS development; and possibly, genetic impact FPG and BP have a relatively minor role in MetS clusters. Our finding also indirectly supports this view as we found triglyceride, HDL-C and WC to be strongly correlated with one another and a relatively weaker correlation for blood pressure and FPG with other traits. More importantly, we also found higher and similar heritability estimates for triglyceride, HDL-C and WC and relatively lower heritability estimates for BP and FPG, suggesting a possible similarity in genetic mechanism of developing MetS for AA population with other ethnic groups.

Our results should be interpreted within the context of few limitations. We acknowledge that given our cross-sectional observational design, our study can only confirm the associations of the factors with MetS; and cannot prove the causality. Our heritability estimates were influenced by shared environmental factors like childhood environment and neighborhood

1  
2  
3 factors, and thus, our results could be slightly overestimated. Nonetheless, even if there was a  
4  
5 possibility of slight overestimation, the complex and extended pedigree structure of JHS with a  
6  
7 large sample provided us a reliable statistical ground to detect genetic effects than nuclear  
8  
9 families, twin pair data or sib-pair data. Further, ascertainment of socio-demographic variables  
10  
11 in the JHS was performed uniformly and precise techniques were used to measure all  
12  
13 physiological and biochemical values, which makes our findings reliable. The present data  
14  
15 although cross-sectional, comes from a large, community-based AA population, who are vastly  
16  
17 understudied. We are not aware of any published data that reported the associated factors and  
18  
19 quantified the heritability of MetS among AA from such a big setting.  
20  
21  
22  
23  
24  
25  
26

27 We found a significant and independent inverse association between MetS and adiponectin; and  
28  
29 a positive association between MetS and homocysteine. In line with our findings, a number of  
30  
31 recent studies also have reported similar results.<sup>46-50</sup> These findings suggest inclusion of  
32  
33 biomarkers like adiponectin and homocysteine to improve early identification of MetS. It was  
34  
35 obvious from our study that social and economic context has disparate impact on women's  
36  
37 cardiovascular health and subsequent policies and health educational programs should be  
38  
39 particularly directed towards women for future CVD risk reduction in AA. As the causes of the  
40  
41 MetS are reversible and the individual components are modifiable, lifestyle change such as  
42  
43 increasing physical activity may reduce the prevalence of MetS. Our results reconfirm that  
44  
45 MetS is a complex disease and though change in lifestyle can modify the risk of MetS, genetic  
46  
47 background also contributes to the development of MetS. Our finding supports the hypothesis  
48  
49 of lipid metabolism playing the central role in the development of MetS and strongly  
50  
51 encourages additional efforts to identify the underlying susceptibility genes for this syndrome  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 in AA. Further exploration of the genetic and environmental factors of the MetS among AA  
4  
5 will lead to a more comprehensive understanding and better therapeutic options for the  
6  
7  
8 syndrome, and ultimately lead to improved cardiovascular health.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Acknowledgments:** This research was supported by the Intramural Research Program of the National Institutes of Health. The Jackson Heart Study is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. We would like to thank the Jackson Heart Study participants and the staff for their important contributions to the study of determinants of health in African Americans.

**Contributorship statement:** SKD and RJK conceptualized the study. RJK and RX completed the main data analysis. RJK and SKD prepared the manuscript. SYG, PC and MS contributed to the study design, interpretation of data, and the preparation of manuscript. All authors read and approved the final manuscript.

**Conflicts of interest:** The authors declare no conflicts of interest.

**Ethics approval:** University of Mississippi Medical Center Institutional Review Board and National Human Genome Research Institute Institutional Review Board

**Data sharing statement:** No additional data available

## References

1. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. *J Diabetes*. 2010;2(3):180-93.
2. Bhargava A. A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study. *Popul Health Metr*. 2003;1(1):3.
3. Carnethon MR, Loria CM, Hill JO, et al. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. *Diabetes Care*. 2004;27(11):2707-15.
4. Sabo RT, Lu Z, Deng X, et al. Parental and offspring associations of the metabolic syndrome in the Fels Longitudinal Study. *Am J Clin Nutr*. 2012;96(3):461-6.
5. Feng Y, Zang T, Xu X. Familial aggregation of metabolic syndrome and its components in a large Chinese population. *Obesity (Silver Spring)*. 2008;16(1):125-9.
6. Santos DM, Katzmarzyk PT, Tregouet DA, et al. Familial aggregation of metabolic syndrome indicators in portuguese families. *Biomed Res Int*. 2013;2013(314823).
7. Bosy-Westphal A, Onur S, Geisler C, et al. Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: the Kiel obesity prevention study. *Int J Obes*. 2007;31(5):784-90.
8. Groop L, Forsblom C, Lehtovirta M, et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. *Diabetes*. 1996;45(11):1585-93.
9. Freeman MS, Mansfield MW, Barrett JH, et al. Heritability of features of the insulin resistance syndrome in a community-based study of healthy families. *Diabet Med*. 2002;19(12):994-9.
10. Bellia A, Giardina E, Lauro D, et al. "The Linosa Study": epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. *Nutr Metab Cardiovasc Dis*. 2009;19(7):455-61.
11. Henneman P, Aulchenko YS, Frants RR, et al. Prevalence and heritability of the metabolic syndrome and its individual components in a Dutch isolate: the Erasmus Rucphen Family study. *J Med Genet*. 2008;45(9):572-7.
12. Lin HF, Boden-Albala B, Juo SH, et al. Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. *Diabetologia*. 2005;48(10):2006-12.
13. Bayoumi RA, Al-Yahyaee SA, Albarwani SA, et al. Heritability of determinants of the metabolic syndrome among healthy Arabs of the Oman family study. *Obesity (Silver Spring)*. 2007;15(3):551-6.
14. Vattikuti S, Guo J, Chow CC. Heritability and genetic correlations explained by common SNPs for metabolic syndrome traits. *PLoS Genet*. 2012;8(3):29.
15. Luke A, Guo X, Adeyemo AA, et al. Heritability of obesity-related traits among Nigerians, Jamaicans and US black people. *Int J Obes Relat Metab Disord*. 2001;25(7):1034-41.
16. Iliadou A, Snieder H, Wang X, et al. Heritabilities of lipids in young European American and African American twins. *Twin Res Hum Genet*. 2005;8(5):492-8.
17. Price RA, Reed DR, Guido NJ. Resemblance for body mass index in families of obese African American and European American women. *Obes Res*. 2000;8(5):360-6.
18. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. *Circulation*. 2013;127(1):e6-e245.
19. van Dongen J, Willemsen G, Chen WM, et al. Heritability of metabolic syndrome traits in a large population-based sample. *J Lipid Res*. 2013;54(10):2914-23.



20. Taylor HA, Jr., Wilson JG, Jones DW, et al. Toward resolution of cardiovascular health disparities in African Americans: design and methods of the Jackson Heart Study. *Ethn Dis*. 2005;15(4 Suppl 6):4-17.
21. Wilson JG, Rotimi CN, Ekunwe L, et al. Study design for genetic analysis in the Jackson Heart Study. *Ethn Dis*. 2005;15(4 Suppl 6):30-37.
22. Taylor HA, Jr. The Jackson Heart Study: an overview. *Ethn Dis*. 2005;15(4 Suppl 6):1-3.
23. Carpenter MA, Crow R, Steffes M, et al. Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study. *Am J Med Sci*. 2004;328(3):131-44.
24. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *Jama*. 2001;285(19):2486-97.
25. Grundy SM, Brewer HB, Jr., Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Arterioscler Thromb Vasc Biol*. 2004;24(2):e13-8.
26. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc Behav*. 1983;24(4):385-96.
27. Dubbert PM, Carithers T, Ainsworth BE, et al. Physical activity assessment methods in the Jackson Heart Study. *Ethn Dis*. 2005;15(4 Suppl 6):56-61.
28. Szabo de Edelenyi F, Goumidi L, Bertrais S, et al. Prediction of the metabolic syndrome status based on dietary and genetic parameters, using Random Forest. *Genes Nutr*. 2008;3(3-4):173-6.
29. Duggirala R, Williams JT, Williams-Blangero S, et al. A variance component approach to dichotomous trait linkage analysis using a threshold model. *Genet Epidemiol*. 1997;14(6):987-92.
30. Metelskaya VA, Shkolnikova MA, Shalnova SA, et al. Prevalence, components, and correlates of metabolic syndrome (MetS) among elderly Muscovites. *Arch Gerontol Geriatr*. 2012;55(2):231-7.
31. Mokan M, Galajda P, Pridavkova D, et al. Prevalence of diabetes mellitus and metabolic syndrome in Slovakia. *Diabetes Res Clin Pract*. 2008;81(2):238-42.
32. Cankurtaran M, Halil M, Yavuz BB, et al. Prevalence and correlates of metabolic syndrome (MS) in older adults. *Arch Gerontol Geriatr*. 2006;42(1):35-45.
33. Luepker RV, Rosamond WD, Murphy R, et al. Socioeconomic status and coronary heart disease risk factor trends. The Minnesota Heart Survey. *Circulation*. 1993;88(5 Pt 1):2172-9.
34. Mackenbach JP, Stirbu I, Roskam AJ, et al. Socioeconomic inequalities in health in 22 European countries. *N Engl J Med*. 2008;358(23):2468-81.
35. Brunner EJ, Marmot MG, Nanchahal K, et al. Social inequality in coronary risk: central obesity and the metabolic syndrome. Evidence from the Whitehall II study. *Diabetologia*. 1997;40(11):1341-9.
36. Berlin I, Lin S, Lima JA, et al. Smoking Status and Metabolic Syndrome in the Multi-Ethnic Study of Atherosclerosis. A cross-sectional study. *Tob Induc Dis*. 2012;10(1):1617-9625.
37. Sun K, Liu J, Ning G. Active smoking and risk of metabolic syndrome: a meta-analysis of prospective studies. *PLoS One*. 2012;7(10):17.
38. Akbartabartoori M, Lean MEJ, Hankey CR. Relationships between cigarette smoking, body size and body shape. *Int J Obes Relat Metab Disord*. 2004;29(2):236-43.
39. Filozof C, Fernandez Pinilla MC, Fernandez-Cruz A. Smoking cessation and weight gain. *Obes Rev*. 2004;5(2):95-103.
40. Poulsen P, Vaag A, Kyvik K, et al. Genetic versus environmental aetiology of the metabolic syndrome among male and female twins. *Diabetologia*. 2001;44(5):537-43.
41. Monda KL, North KE, Hunt SC, et al. The genetics of obesity and the metabolic syndrome. *Endocr Metab Immune Disord Drug Targets*. 2010;10(2):86-108.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
42. Kristiansson K, Perola M, Tikkanen E, et al. Genome-Wide Screen for Metabolic Syndrome Susceptibility Loci Reveals Strong Lipid Gene Contribution But No Evidence for Common Genetic Basis for Clustering of Metabolic Syndrome Traits. *Circulation: Cardiovascular Genetics*. 2012;5(2):242-49.
43. Joy T, Lahiry P, Pollex RL, et al. Genetics of metabolic syndrome. *Curr Diab Rep*. 2008;8(2):141-8.
44. Povel CM, Boer JM, Reiling E, et al. Genetic variants and the metabolic syndrome: a systematic review. *Obes Rev*. 2011;12(11):952-67.
45. Lyssenko V, Sjögren M, Almgren P, et al. Genetic prediction of the metabolic syndrome. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2008;2(4):245-52.
46. Kim JY, Ahn SV, Yoon JH, et al. Prospective study of serum adiponectin and incident metabolic syndrome: the ARIRANG study. *Diabetes Care*. 2013;36(6):1547-53.
47. Juonala M, Saarikoski LA, Viikari JS, et al. A longitudinal analysis on associations of adiponectin levels with metabolic syndrome and carotid artery intima-media thickness. The Cardiovascular Risk in Young Finns Study. *Atherosclerosis*. 2011;217(1):234-9.
48. Barazzoni R, Silva V, Singer P. Clinical biomarkers in metabolic syndrome. *Nutr Clin Pract*. 2014;29(2):215-21.
49. Hajer GR, van der Graaf Y, Olijhoek JK, et al. Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome. *Heart*. 2007;93(2):216-20.
50. Esteghamati A, Hafezi-Nejad N, Zandieh A, et al. Homocysteine and metabolic syndrome: From clustering to additional utility in prediction of coronary heart disease. *Journal of Cardiology*. 0)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
√ <b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
√ <b>Introduction</b>		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
√ <b>Methods</b>		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses
√ <b>Results</b>		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

<b>√Discussion</b>		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
<b>√Other information</b>		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Prevalence, Associated Factors and the Heritability of Metabolic Syndrome and its Individual Components in African Americans: The Jackson Heart Study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2015-008675.R1
Article Type:	Research
Date Submitted by the Author:	08-Jul-2015
Complete List of Authors:	Khan, Rumana; National Institutes of Health, National Human Genome Research Institute Gebreab, Samson; National Institutes of Health, National Human Genome Research Institute Sims, Mario; University of Mississippi Medical Center, Department of Internal Medicine Crespo, Pia; National Institutes of Health, National Human Genome Research Institute Xu, Ruihua; National Institutes of Health, National Human Genome Research Institute Davis, Sharon; National Institutes of Health, National Human Genome Research Institute
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Public health
Keywords:	Metabolic Syndrome, African Americans, Heritability

SCHOLARONE™  
Manuscripts

**Title page:****Title: Prevalence, Associated Factors and the Heritability of Metabolic Syndrome and its Individual Components in African Americans: The Jackson Heart Study****Corresponding author:**

Rumana J Khan

Cardiovascular Section

Genomics of Metabolic, Cardiovascular and Inflammatory Disease Branch, Social Epidemiology

Research Unit, National Human Genome Research Institute, 10 Center Drive, Room 7N316

MSC 1644, Bethesda, MD 20892

e-mail address: rumana.khan@nih.gov

Main: 301-451-2447

Direct: 301-451-2127

Fax: 301-480-0063

**Author names and affiliations****Rumana J Khan, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,

National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,

USA.

**Samson Y Gebreab, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,  
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,  
USA.

**Mario Sims, PhD**

Division of Hypertension, Department of Internal Medicine, University of Mississippi Medical  
Center, Jackson, Mississippi, USA

**Pia R Crespo, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,  
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,  
USA.

**Ruihua Xu, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,  
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,  
USA.

**Sharon K Davis, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,  
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,  
USA.

**Keywords:** Metabolic Syndrome, African Americans, Heritability, Associated factors

**Word count:**

The total word count of text: 2965

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Abstract

**Objective:** Both environmental and genetic factors play important roles in development of metabolic syndrome (MetS). Studies about its associated factors and genetic contribution in African Americans (AA) are sparse. Our aim was to report the prevalence, associated factors and heritability estimates of MetS and its components in AA.

**Participants and setting:** Data of this cross-sectional study comes from large and community based Jackson Heart Study (JHS). We analyzed a total of 5227 participants, of which 1636 from 281 families were part of the family study subset of JHS.

**Methods:** Participants were classified as having the MetS according to the Adult Treatment Panel III criteria. Multiple logistic regression analysis was performed to isolate independently associated factors of MetS (n=5227). Heritability was estimated from the family study subset using variance component methods (n=1636).

**Results:** About 27% of men and 40% of women had MetS. For men, associated factors with having MetS were older age, lower physical activity, higher body mass index, higher homocysteine and adiponectin level ( $p<0.05$  for all). For women, in addition to all these, lower education, current smoking, and higher stress were also significant ( $p<0.05$  for all). After adjusting for covariates, the heritability of MetS was 32% ( $p<0.001$ ). Heritability ranged from 14 to 45% among its individual components. Relatively higher heritability was estimated for waist circumference (45%), high density lipoprotein-cholesterol (43%) and triglycerides (42%). Heritability of systolic blood pressure (BP), diastolic BP, and fasting blood glucose were 16%, 15%, and 14%, respectively.

**Conclusion:** Stress and low education were associated with having MetS in AA women, but not in men. Higher heritability estimates for lipids and waist circumference supports the hypothesis

1  
2  
3 of lipid metabolism playing the central role in the development of MetS and encourages  
4  
5 additional efforts to identify the underlying susceptibility genes for this syndrome in AA.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Strengths and limitations of this study

- African American community disproportionately suffers from metabolic syndrome, but relatively little is known about the genetic contribution and the environmental influence of this syndrome among African Americans.
- Using the data from large, community-based Jackson Heart study, this study showed a high prevalence of metabolic syndrome, and reported the associated factors and heritability estimates of metabolic syndrome and its components in African Americans.
- We are not aware of any published data that explored these issues among African American from such a big setting. The large sample size also provided a reliable statistical ground to detect heritability estimates than nuclear families, twin pair data or sib-pair data.
- Potential limitations of this study included the cross-sectional observational design, which could only confirm the associations of the factors with metabolic syndrome, but not the causality, and the absence of information on shared environmental factors like childhood environment and neighborhood factors, which might slightly overestimate the heritability results.
- This study encourages additional efforts to identify the underlying susceptibility genes for metabolic syndrome among African Americans.

## BACKGROUND

Metabolic syndrome (MetS) is a clustering of different interrelated cardio-metabolic risk factors including obesity, elevated blood pressure (BP), dyslipidemia, and impaired fasting plasma glucose (IFG). These risk factors often occur together and increases cardiovascular disease (CVD) deaths almost by three to four fold.<sup>1,2</sup> As MetS is the combined effect of more than one risk factor, the etiology of the MetS is complex. Factors like lifestyle, gender, ethnicity, socioeconomic status, psychosocial factors and some inflammatory markers play key roles in the pathogenesis of MetS.<sup>1-3</sup> Findings also suggest that MetS clusters in families<sup>4-8</sup> and has reasonable heritability, which is defined as the proportion of phenotypic variance in a trait that is attributable to the additive effects of genes.<sup>9-17</sup> Thus, the interplay of both environmental and genetic factors makes MetS a multifactorial disorder.

Though the pathogenesis, diagnosis and the treatment of MetS remain complex because of its multifactorial nature, the construct MetS is an important risk-assessment method for early detection and early intervention of CVD. In spite of steady decline in CVD mortality during recent decades, CVD is still the leading cause of death in all Americans, and is highly prevalent in persons of African ancestry.<sup>18</sup> It is important to note that the majority of studies that explored the associated factors and quantified the heritability of MetS almost exclusively involved Caucasians.<sup>10-14, 19</sup> Relatively little is known about these issues among adult African American (AA) population.<sup>15-17</sup> Using the Jackson Heart Study (JHS) data, the objective of this cross-sectional study was to report the prevalence, risk factors and heritability estimates of MetS and its components in AA.

## METHODS

### Data Source

Data of this analysis comes from large and community based JHS, which comprises 5301 adult AA enrolled between September 2000 and March 2004 residing in Jackson, Mississippi, metropolitan area.<sup>20</sup> About 24% of 5301 participated in the JHS family study component.<sup>21</sup> The family study component of JHS contained 1st degree (parent-offspring and siblings), 2nd degree (grandparent-grandchild, avuncular, half-siblings) and 3rd degree or more distant (great grandparent-grandchild, grand avuncular, half avuncular, first cousins, half first cousins, second cousins) family members. The JHS was approved by the University of Mississippi Medical Center Institutional Review Board, and the participants gave written informed consent. Details of the study design and data collection methods are described elsewhere.<sup>21, 22</sup> The current study data were obtained from the baseline clinic visit during 2000-2004. After excluding 74 participants who didn't have information on their MetS status, the current analysis had a total of 5227 participants, of which 1636 from 281 families contributed to the heritability analyses.

### Measures

We collected information on participant's waist circumference (WC), systolic BP (SBP) and diastolic BP (DBP), fasting plasma glucose (FPG), fasting triglyceride, and plasma high-density lipoprotein cholesterol (HDL-C). Two measures of the waist at the level of the umbilicus and in the upright position were averaged to calculate WC. Sitting BP was measured twice at 5-min intervals with a standardized Hawksley random-zero sphygmomanometer, and

1  
2  
3 the average of two measurements was used. Fasting blood samples were collected according to  
4  
5 standardized protocols, and the assessments of FPG and lipids were processed at the Central  
6  
7 Laboratory, University of Minnesota.<sup>23</sup> Respondents were asked about their medication usage  
8  
9 for hypertension, diabetes mellitus and high lipid levels. Individuals were classified as having  
10  
11 MetS if they had at least three of the following five components: (1) large WC or abdominal  
12  
13 obesity (> 102 cm for men and > 88 cm for women); (2) hypertriglyceridemia (fasting plasma  
14  
15 triglyceride concentration  $\geq$  150 mg/dL or on drug treatment); (3) low HDL-C levels (< 40  
16  
17 mg/dL for men and < 50 mg/dL in women or on drug treatment); (4) elevated BP ( $\geq$  130 mm  
18  
19 Hg SBP or  $\geq$  85 mm Hg DBP or on drug treatment); or, (5) IFG ( $\geq$  110 mg/dL or on drug  
20  
21 treatment).<sup>24, 25</sup>  
22  
23  
24  
25  
26  
27  
28

29 Data about socio-demographic (age, sex, and education), the psychosocial (stress) and lifestyle  
30  
31 (physical activity, smoking status, and alcohol consumption) variables were also collected. Age  
32  
33 was classified as: 20-39, 40-59, 60-79 and 80 years and above. Education status was self-  
34  
35 reported and was divided into three categories (less than high school, high school/GED/ some  
36  
37 college and college/associate degree or higher, where less than high school was the referent).  
38  
39 Stress level was obtained from The Global Perceived Stress Scale, an 8-item questionnaire that  
40  
41 measures the severity of chronic stress experienced over a prior period of twelve months.<sup>26</sup> The  
42  
43 physical activity index composite score was calculated as the sum of four different domains of  
44  
45 physical activity: active living, work, home and garden, and sport and exercise indices.<sup>27</sup>  
46  
47  
48 Smoking status was classified as never (referent), current, and former. Alcohol consumption  
49  
50 status was defined as “yes” if they currently consumed alcoholic beverages and “no” (referent)  
51  
52  
53 if they had stopped drinking for more than a year, or if they never consumed alcohol.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Information on clinical factors like body mass index or BMI (weight in kg divided by height in  
4  
5 meter square), C-reactive protein or CRP (mg/dL), serum adiponectin (mg/dL), and serum  
6  
7 homocysteine (umol/L) were also obtained.<sup>23</sup>  
8  
9

## 10 11 12 **Analysis**

13  
14 Data from the full cohort (n= 5227) were used to explore the risk factors of MetS. Socio-  
15  
16 demographic, psychosocial, lifestyle and clinical characteristics of participants were compared  
17  
18 by gender and MetS status using the chi-square or independent t-test. The primary outcome  
19  
20 measure for this analysis was the presence of MetS, evaluated as a dichotomous variable.  
21  
22 Logistic regression analysis was used to examine the association between each independent  
23  
24 variable (age, education level, stress level, physical activity score, smoking status, alcohol  
25  
26 consumption status, BMI, CRP, fasting total cholesterol, serum concentration of adiponectin,  
27  
28 and serum homocysteine) with the outcome of MetS. A multiple logistic regression model was  
29  
30 fitted including all variables to isolate the statistically significant predictors of MetS.  
31  
32  
33  
34  
35  
36  
37  
38

## 39 **Heritability Analysis**

40  
41 After checking the pedigree data for inconsistencies a total of 1636 individuals from 281  
42  
43 families were analyzed to calculate the heritabilities by variance component methods using  
44  
45 SOLAR (Sequential Oligogenic Linkage Analysis Routines) software to quantify the proportion  
46  
47 of the variance in MetS and in its individual components that was attributable to the additive  
48  
49 effects of genes.<sup>28</sup> We estimated the heritability of individual MetS components (treated as  
50  
51 continuous variable) including WC, SBP, DBP, FPG, fasting triglyceride, and plasma HDL-C  
52  
53 with adjustment for age, education level, physical activity index composite score, smoking  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 status, alcohol consumption status and respective medication usage. Log transformed values of  
4  
5 FPG and triglycerides were used due to deviation from normal distribution. Heritabilities were  
6  
7 calculated using a standard quantitative genetic variance-components model implemented in  
8  
9 SOLAR.<sup>28</sup> This approach uses the maximum-likelihood estimation to a mixed-effects model  
10  
11 that incorporates fixed covariate effects, additive genetic effects and residual error. The  
12  
13 heritability of MetS (discrete variable) was analyzed by a threshold model in SOLAR. The  
14  
15 method assumed that an individual belonged to a specific affected status if an underlying  
16  
17 genetically determined risk exceeded a certain threshold.<sup>29</sup>  
18  
19  
20  
21  
22  
23  
24

## 25 RESULTS

26  
27 Of the 5227 individuals, 1909 (36.52%, mean age 53.93 years and standard deviation or  
28  
29 SD=12.93) were men and 3318 (63.48%, mean age 55.30 ±12.76) were women. Education  
30  
31 level were similar for men and women (Table 1). About 40% of men and women had college  
32  
33 level education or beyond. A clear gender difference however, was found for alcohol use and  
34  
35 smoking, with women being far less likely than men to consume alcohol and smoke cigarettes  
36  
37 (p<0.001). Women reported greater levels of stress, but lower level of physical activity than  
38  
39 men (p<0.001). Women also had higher BMI, CRP, adiponectin, and lower homocysteine level  
40  
41 than men (p<0.001 for all). Table 1 also shows the prevalence of MetS and its individual  
42  
43 components among the JHS participants. About 27.34% of the men and 38.94% of the women  
44  
45 had MetS (p<0.001). In terms of individual components, women had higher abdominal obesity  
46  
47 (75.70% versus 41.03%, p<0.001) and IFG (22.45% versus 19.64%, p<0.001), but lower  
48  
49 hypertriglyceridemia (13.23% versus 18.39%, p <0.001) than men.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Table 1:

## Characteristics of Participants of the Jackson Heart Study by Gender (N=5227)

	Men <sup>a</sup> n=1909	Women <sup>a</sup> n=3318	P value <sup>b</sup>
<b>Age in years</b>	53.93 (12.93)	55.30 (12.76)	0.0002
<b>Education level</b>			
Less than high school	18.73	17.88	
High school/GED or some college	42.82	41.83	
College/associate degree or higher	38.45	40.29	0.4094
<b>Smoking Status</b>			
Never	56.68	74.59	
Former	25.33	15.30	
Current	17.99	10.11	<.0001
<b>Alcohol drinking status</b>			
Yes	58.92	38.41	
No	41.08	61.59	<.0001
<b>Total Physical Activity Score<sup>c</sup></b>	8.64 (2.63)	8.16 (2.58)	<.0001
<b>Global Stress Total Score<sup>d</sup></b>	4.50 (4.20)	5.52 (4.45)	<.0001
<b>Body mass index (weight in kg/height in squared meter)</b>	29.83±6.14	32.86 (7.59)	<.0001
<b>High Sensitivity C-Reactive Protein in mg/dL</b>	0.35 (0.96)	0.60 (0.85)	<.0001
<b>Homocysteine in umol/L</b>	10.17 (3.56)	9.00 (5.20)	<.0001
<b>Adiponectin level in µg/mL</b>	4.15 (3.41)	6.15 (4.57)	<.0001
<b>Abdominal obesity<sup>e</sup></b>	41.03	75.70	<.0001
<b>Hypertriglyceridemia</b>	18.39	13.23	<.0001
<b>Low HDL-C<sup>g</sup></b>	33.01	39.55	<.0001
<b>Elevated blood Pressure<sup>h</sup></b>	69.62	70.58	0.4616
<b>impaired fasting glucose<sup>i</sup></b>	19.64	22.45	0.0171
<b>Metabolic syndrome<sup>k</sup></b>	27.34	38.94	<.0001

<sup>a</sup>Data presented as mean (SD) or percentage of subjects

<sup>b</sup>Independent t-test or Chi-square test;

<sup>c</sup>sum of the four different domains of physical activity;

<sup>d</sup>sum of 8 item questionnaire that measures the severity of chronic stress experienced over a prior period of twelve months;

<sup>e</sup>waist circumference > 102 cm for men and > 88 cm for women

<sup>f</sup>fasting plasma triglyceride concentration ≥ 150 mg/dL or on drug treatment

<sup>g</sup>HDL cholesterol levels <40 mg/dL for men and < 50 mg/dL in women or on drug treatment

<sup>h</sup>Blood pressure ≥ 130 mm Hg systolic or ≥ 85 mm Hg diastolic or on drug treatment

<sup>i</sup>fasting glucose ≥ 110 mg/dL or on drug treatment

<sup>k</sup>Metabolic Syndrome defined as having at least three of the following five components: (1) abdominal obesity; (2) hypertriglyceridemia; (3) low HDL cholesterol levels; (4) elevated blood; (5) impaired fasting glucose

1  
2  
3 Table 2 shows the descriptive characteristics of participants by MetS status. Those who had  
4  
5 MetS were older, less educated, less likely to smoke, less likely to consume alcohol, and less  
6  
7 physically active ( $p < 0.001$  for all). They also had higher BMI, higher CRP and higher  
8  
9 homocysteine level; but lower adiponectin concentration ( $p < 0.001$  for all). The unadjusted and  
10  
11 the adjusted relationships of MetS with these features are displayed in Table 3. After  
12  
13 adjustment, older age remained significant for both men and women. Notably, the trend of  
14  
15 having MetS with increasing age was clearer for women than for men. Education was only  
16  
17 significant for women, and not for men. Women who went to high school had 24% (adjusted  
18  
19 odds ratio or AOR: 0.76; 95% confidence interval or CI: 0.59-0.97) decreased odds of having  
20  
21 MetS compared to those who had the lowest education level. Like education, higher stress level  
22  
23 was also a significant factor for women only (AOR: 1.02; 95% CI: 1.01-1.04). Physical activity  
24  
25 decreased the odds of having MetS for both sexes, but alcohol consumption was associated  
26  
27 with 26% decreased odds (AOR: 0.74; 95% CI: 0.61-0.90) of MetS for women only.  
28  
29 Relationship between smoking and MetS was different for men and women. While current  
30  
31 smoking only predicted women's MetS (AOR: 1.43; 95% CI: 1.07-1.91), former smoking had  
32  
33 significant association with men's MetS (AOR: 1.54 ; 95% CI: 1.14-2.08). Biomedical risk  
34  
35 factors such as increased BMI (AOR: 1.18; 95% CI: 1.15-1.21 for men and AOR: 1.08; 95%  
36  
37 CI: 1.07-1.10 for women), increased serum homocysteine (AOR: 1.05; 95% CI: 1.02-1.09 for  
38  
39 men and AOR: 1.06; 95% CI: 1.03-1.09 for women) and decreased serum adiponectin  
40  
41 (AOR: 0.90; 95% CI: 0.85-0.95 for men and AOR: 0.90; 95% CI: 0.87-0.92 for women) were  
42  
43 associated with increased odds of having MetS for both sexes.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2: Characteristics of Jackson Heart Study Participants by metabolic syndrome status (N=5227)**

	<b>Metabolic Syndrome<sup>a</sup> (n=1814)</b>	<b>No Metabolic Syndrome<sup>a</sup> (n=3413)</b>	<b>P value<sup>b</sup></b>
<b>Age in years</b>	58.04 (11.43)	53.07 (13.21)	<.0001
<b>Gender of Participant</b>			
Men	28.78	40.46	
Women	71.22	59.36	<.0001
<b>Education level</b>			
Less than high school	23.32	15.46	
High school/GED or some college	41.94	42.33	
College/associate degree or higher	34.74	42.21	<.0001
<b>Smoking Status</b>			
Never	66.17	69.05	
Former	21.59	17.56	
Current	12.24	13.39	0.0017
<b>Alcohol drinking status</b>			
Yes	37.01	50.63	
No	62.99	49.37	<.0001
<b>Total Physical Activity Score<sup>c</sup></b>	7.74 (2.56)	8.65 (2.57)	<.0001
<b>Global Stress Total Score<sup>d</sup></b>	5.11 (4.42)	5.17 (4.37)	0.6251
<b>Body mass index (weight in kg/height in squared meter)</b>	34.87 (6.92)	30.10 (6.86)	<.0001
<b>High Sensitivity C-Reactive Protein in mg/dL</b>	0.65 (1.13 )	0.44 (0.74)	<.0001
<b>Homocysteine: The concentration of homocysteine in umol/L</b>	9.94 (6.37)	9.15 (3.44)	<.0001
<b>Serum concentration of adiponectin in µg/mL</b>	4.72 (4.02)	5.79 (4.38)	<.0001

<sup>a</sup>Data presented as mean (SD) or percentage of subjects

<sup>b</sup>Independent t-test or Chi-square test;

<sup>c</sup>sum of the four different domains of physical activity;

<sup>d</sup>sum of 8 item questionnaire that measures the severity of chronic stress experienced over a prior period of twelve months;

**Table 3: Association between selected factors and prevalence of metabolic Syndrome among Jackson Heart Study Participants (n=5227)**

	Metabolic Syndrome Odds Ratio (95% CI)			
	Men (n=1909)		Women (n=3318)	
	Unadjusted <sup>a</sup>	Adjusted <sup>a</sup>	Unadjusted <sup>a</sup>	Adjusted <sup>a</sup>
<b>Age</b>	Reference Level		Reference Level	
20-39	Reference Level		Reference Level	
40-59	1.34(0.96-1.86)	1.55 (1.02-2.35)	2.44(1.84-3.23)	2.79 (2.00 -3.87)
60-79	1.69(1.20-2.38)	2.17 (1.34-3.51)	4.69(3.54-6.22)	5.50 (3.81-7.93)
80 and above	0.88(0.28-2.71)	2.18 (0.60-8.00)	3.43(1.89-6.24)	5.06 (2.34-10.96)
<b>Education</b>	Reference Level		Reference Level	
Less than High school	Reference Level		Reference Level	
High school or some College	0.95(0.72-1.25)	1.20 (0.83-1.74)	0.53(0.44-0.65)	0.76 (0.59- 0.97)
College degree or higher	0.79(0.60-1.05)	1.05 (0.72 1.55)	0.44(0.36-0.53)	0.82 (0.63-1.07)
<b>Smoking Status</b>	Reference Level		Reference Level	
Never	Reference Level		Reference Level	
Former	1.47(1.16-1.85)	1.54 (1.14-2.08)	1.39(1.15-1.69)	1.20 (0.95-1.52)
Current	0.92(0.69-1.22)	1.29 (0.89-1.86)	1.20(0.95-1.51)	1.43 (1.07-1.91)
<b>Alcohol drinking</b>	Reference Level		Reference Level	
No	Reference Level		Reference Level	
Yes	0.72(0.59-0.88)	0.85 (0.66-1.11)	0.57(0.49-0.66)	0.74 (0.61-0.90)
<b>Physical Activity<sup>b</sup></b>	0.90(0.86-0.94)	0.93 (0.88- 0.98)	0.86(0.84-0.89)	0.94 (0.91-0.98)
<b>Global Stress<sup>c</sup></b>	1.01(0.98-1.03)	1.02 (0.99-1.06)	0.98(0.97-1.00)	1.02 (1.01- 1.04)
<b>Body mass index</b>	1.18(1.15-1.20)	1.18 (1.15-1.21)	1.08(1.07-1.09)	1.08 (1.07-1.10)
<b>C-Reactive Protein in mg/dL</b>	1.36(1.15-1.60)	1.10 (0.96- 1.26)	1.29(1.18-1.41)	0.99 (0.89-1.09)
<b>Homocysteine in umol/L</b>	1.04(1.01-1.07)	1.05 (1.02 1.09)	1.07(1.05-1.10)	1.06(1.03-1.09)
<b>Adiponectin in µg/mL</b>	0.89(0.85-0.92)	0.90 (0.85-0.95)	0.91(0.90-0.93)	0.90 (0.87-0.92)

Metabolic Syndrome defined as having at least three of the following five components: (1) abdominal obesity or large waist circumference (> 102 cm for men and > 88 cm for women); (2) hypertriglyceridemia (fasting plasma triglyceride concentration  $\geq$  150 mg/dL or on drug treatment); (3) low HDL cholesterol levels (< 40 mg/dL for men and < 50 mg/dL in women or on drug treatment); (4) elevated blood pressure ( $\geq$  130 mm Hg systolic or  $\geq$  85 mm Hg diastolic or on drug treatment); or, (5) IFG or impaired fasting glucose (110 mg/dL or on drug treatment)

<sup>a</sup>Analysis done using simple and multiple logistic regression. The multivariate models are adjusted for for all other variables in the table.

<sup>b</sup>sum of the four different domains of physical activity;

<sup>c</sup>sum of 8 item questionnaire that measures the severity of chronic stress experienced over a prior period of twelve months;

1  
2  
3  
4  
5  
6 Table 4 illustrates the heritability estimates along with the proportion of variation explained by  
7  
8 covariates ( $\sigma_e^2$ ) of MetS and its individual component in the family study subset (n=1636). All  
9  
10 components of the MetS were significantly correlated with each other except for the pairs of  
11  
12 blood pressure and HDL-C and blood pressure and fasting glucose (results not shown in table).  
13  
14 After accounting for the covariates (except medication), the heritability of MetS was about 32%  
15  
16 (p<0.0001,  $\sigma_e^2$ : 10%). The adjusted heritability of individual MetS components ranged from the  
17  
18 lowest of 14% (p<0.01,  $\sigma_e^2$ : 33%) for FPG to the highest of 45% (p<0.0001,  $\sigma_e^2$ : 8%) for WC  
19  
20 after adjusting for all the covariates. The adjusted estimates of DBP (15%, p<0.01,  $\sigma_e^2$ : 9%) and  
21  
22 SBP (16%, p<0.001,  $\sigma_e^2$ : 22%) were on the lower end and similar to the estimate of FPG.  
23  
24 Conversely, heritability of triglyceride (42%, p<0.001,  $\sigma_e^2$ : 10%) and HDL-C (43%, p<0.001,  
25  
26  $\sigma_e^2$ : 11%) was relatively high and similar to the heritability of WC.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 4: Heritability estimates of Metabolic Syndrome and its individual components of Jackson Heart Study Participants (n=1636)**

	Heritability Estimate	Standard error	P value	Proportion of variation explained by covariates
<b>Metabolic Syndrome<sup>a</sup></b>	0.32	0.08	<0.0001	0.10 <sup>e</sup>
<b>Fasting Plasma Glucose<sup>b,c</sup></b>	0.14	0.06	<0.01	0.33 <sup>d</sup>
<b>Waist Circumference<sup>b</sup></b>	0.45	0.06	<0.0001	0.08 <sup>e</sup>
<b>High Density Lipoprotein Cholesterol<sup>b</sup></b>	0.43	0.07	<0.0001	0.11 <sup>d</sup>
<b>Fasting Triglyceride<sup>b,c</sup></b>	0.42	0.05	<0.0001	0.10 <sup>d</sup>
<b>Systolic blood pressure<sup>b</sup></b>	0.16	0.07	<0.001	0.22 <sup>d</sup>
<b>Diastolic blood pressure<sup>b</sup></b>	0.15	0.05	<0.01	0.09 <sup>d</sup>

<sup>a</sup>Treated as discrete trait, and defined as having at least three of the following five components: (1) abdominal obesity or large waist circumference (> 102 cm for men and > 88 cm for women); (2) hypertriglyceridemia (fasting plasma triglyceride concentration  $\geq$  150 mg/dL or on drug treatment); (3) low HDL cholesterol levels (< 40 mg/dL for men and < 50 mg/dL in women or on drug treatment); (4) elevated blood pressure ( $\geq$  130 mm Hg systolic or  $\geq$  85 mm Hg diastolic or on drug treatment); or, (5) IFG or impaired fasting glucose (110 mg/dL or on drug treatment)

<sup>b</sup>Treated as continuous trait

<sup>c</sup>Log transformed

<sup>d</sup> Covariates are age, sex, education, smoking status, alcohol intake, physical activity and respective medication

<sup>e</sup> Covariates are age, sex, education, smoking status, alcohol intake, physical activity

## DISCUSSION

We provide here the epidemiological and heritability data about MetS and its related traits according ATP III criteria among AA. Overall, in our study sample, the prevalence of MetS was higher among women than men. Factors independently associated with having MetS for men were older age, lower physical activity level, higher BMI, higher level of homocysteine and lower level of adiponectin. For women, in addition to older age, lower physical activity level, higher BMI, higher level of homocysteine and lower level of adiponectin, , low education, higher stress, current smoking and alcohol consumption were also significant. The

1  
2  
3 heritability of the MetS was 32% and among its individual components, heritability ranged  
4  
5 from 14% for FPG to 45% for WC.  
6  
7  
8  
9

10 The prevalence of MetS that we found (38.94% of women and 27.34% of men) was almost  
11  
12 identical to a recent estimate from a National Survey, which reported 38.2% of AA women and  
13  
14 25.5% of AA men had MetS.<sup>1</sup> A higher prevalence of MetS in women than in men has been  
15  
16 reported in several other Asian and Eastern European countries, as well as among Hispanic, and  
17  
18 Native Americans.<sup>1, 30-32</sup> However, it is opposite for US Caucasians with higher prevalence in  
19  
20 men.<sup>1</sup> This, together with our finding suggest the possibility of an increased risk of MetS for  
21  
22 women belonging to an economically disadvantaged or a minority population group. The  
23  
24 unfavorable condition of women was also evident from our multivariate analysis, where we  
25  
26 found lower education and stress to be significantly related with MetS for women, but not for  
27  
28 men. While in the industrialized society social class and education are typically inversely  
29  
30 related to different cardio-metabolic risk factors regardless of gender,<sup>33-35</sup> in our study, this was  
31  
32 true only for women, indicating an adverse social environment of our women participants.  
33  
34  
35  
36  
37  
38  
39  
40

41 Literature have indicated active smoking to be associated with development of MetS.<sup>36, 37</sup> We  
42  
43 however found, active smoking to be associated with women's MetS only. The lack of  
44  
45 association between current smoking and MetS among men in our study can be partly attributed  
46  
47 to the much discussed inverse association between active smoking and obesity as the smoking  
48  
49 prevalence was higher and abdominal obesity was relatively lower in the men than women in  
50  
51 our analysis.<sup>38</sup> Further, researchers have also found smoking cessation to be frequently  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 followed by weight gain,<sup>39</sup> which explains our observed association between past smoking and  
4  
5 men's MetS.  
6  
7  
8  
9

10 Although lifestyle, physiological and socio-demographic factors play key roles in the  
11 pathogenesis of MetS, there is also strong evidence that the syndrome is inherited.<sup>40-43</sup> We  
12 evaluated the contributions of genetic factors to the phenotypic variability of MetS and its traits  
13 by heritability estimation. According to various studies from different ethnic groups,  
14 heritability of MetS ranges from approximately 19 to 38%.<sup>10-13</sup> A Dutch study estimated a  
15 heritability of 19.2% of MetS in an isolated group of population.<sup>11</sup> A heritability of 24% in a  
16 Caribbean-Hispanic population has been reported by Lin et al.<sup>12</sup> The heritability for the  
17 Caucasian population was about 27% according to large population based study.<sup>10</sup> Bayoumi et  
18 al. reported a heritability of 38% of MetS in healthy Omani Arab families.<sup>13</sup> Besides the genetic  
19 effect itself, which could be different among different studied populations, the discrepancy in  
20 heritability might be attributable to other factors such as different sample sizes, different  
21 structure of pedigrees or covariates included in the analysis. Compared to different ethnic  
22 groups, relatively little information is available on the heritability of MetS in AA population.  
23 The heritability of MetS in our study was 32% after taking into account the contributions of  
24 covariates, like age, sex, alcohol consumption, smoking and physical activity level, suggesting  
25 that more than one-third of the variance in MetS was attributable to the additive effects of  
26 genes in the JHS participants. This estimate is on the higher end of the heritability range  
27 reported so far, which suggests significant genetic influences on clustering of risk factors  
28 among AA.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Reported heritability from different studies for the individual traits ranges from 10% for plasma glucose to 60% for HDL-C.<sup>10-14, 19</sup> Our estimates correspond well with these findings. In the present study, more than 40% of the variance in HDL-C, triglyceride and WC was attributable to genetic effect. Conversely, a moderate but significant heritability were observed for BP and FPG. In different studies as well, HDL-C, obesity and lipid profiles showed the strongest heritability, and BP and FPG had the lowest heritability.<sup>10-14</sup> While for lipid levels and WC genetic influence remains dominant; it seems, for FPG and BP the environmental contribution play a more prominent role, which was apparent by the remarkable covariate effect that was observed for FPG and BP (33% and 22%, respectively) not only in our findings, but also in some other studies.<sup>10, 12</sup> This hypothesis is further supported by some genetic association studies, where investigators have tried to find a unifying pathogenic mechanism for the different MetS components and identify genetic variants contributing to MetS. No such work among AA were found, but a meta-analysis of 4000 Asian and Caucasian participants reviewing 25 genes reported an association between MetS and single nucleotide polymorphisms in the FTO, TCFL72, IL6, APOA5, APOC3 and CETP genes.<sup>44</sup> Another Swedish study found that genetic variants in the PPARG and ADRB1 genes conferred an increased risk of future MetS<sup>45</sup>. All of these genes are mostly involved in lipid metabolism<sup>44, 45</sup>. These evidence indicate that lipid metabolism plays the central role in MetS development; and possibly, genetic impact FPG and BP have a relatively minor role in MetS clusters. Our finding also indirectly supports this view as we found triglyceride, HDL-C and WC to be strongly correlated with one another and a relatively weaker correlation for blood pressure and FPG with other traits. More importantly, we also found higher and similar heritability estimates for triglyceride, HDL-C and WC and relatively lower heritability estimates for BP and FPG,

1  
2  
3 suggesting a possible similarity in genetic mechanism of developing MetS for AA population  
4  
5 with other ethnic groups.  
6  
7  
8  
9

10 Our findings reconfirm that MetS is a complex disease and lifestyle, SES, and genetic  
11 background play important roles in the development of MetS. It was obvious from our study  
12 that social and economic context has disparate impact on women's cardiovascular health and  
13 subsequent policies and health educational programs should be particularly directed towards  
14 women for future CVD risk reduction. As the causes of the MetS are reversible and the  
15 individual components are modifiable, lifestyle change such as increasing physical activity may  
16 reduce the prevalence of MetS in AA people. We found a significant and independent inverse  
17 association between MetS and adiponectin; and a positive association between MetS and  
18 homocysteine. In line with our findings, a number of recent studies also have reported similar  
19 results.<sup>46-50</sup> These findings suggest, monitoring circulating adiponectin and homocysteine level  
20 could provide useful clinical information on risk of developing MetS and provide effective  
21 targets for intervention aimed at modifying lifestyle. However, further studies, including  
22 economic evaluations and prospective studies should investigate whether these markers would  
23 prove useful and cost effective in the early identification of MetS. In the present study we  
24 found considerable heritability of MetS among AA. This provides direct support for performing  
25 genome-wide association studies in this population. Our finding also supports the hypothesis of  
26 lipid metabolism playing the central role in the development of MetS and strongly encourages  
27 additional efforts to identify the underlying susceptibility genes for this syndrome in AA.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Our results should be interpreted within the context of few limitations. We acknowledge that  
4 given our cross-sectional observational design, our study can only confirm the associations of  
5 the factors with MetS; and cannot prove the causality. We also recognize the considerable  
6 disagreement over the definition and diagnostic criteria related to MetS. Of the various  
7 available definitions, we used the ATP III criteria as this is the most widely used definition in  
8 the US<sup>1,24</sup>. It can be, however, argued that some other available definition of MetS could be  
9 equally valid and produce somewhat different result. Though we have accounted for important  
10 individual covariates, our heritability estimates were influenced by shared environmental  
11 factors like childhood environment and neighborhood factors, and thus, our results could be  
12 slightly overestimated. One of the major strengths of our study is, our data although cross-  
13 sectional, comes from a large, community-based AA population, who are vastly understudied  
14 but have high prevalence of metabolic diseases including obesity, diabetes, hypertension and  
15 others. We are not aware of any published data that reported the associated factors and  
16 quantified the heritability of MetS among AA from such a big setting. Further, assessment of  
17 socio-demographic variables in the JHS was performed uniformly and precise techniques were  
18 used to measure all physiological and biochemical values, which makes our findings reliable.  
19 JHS also has a complex and extended pedigree structure with a large sample, which provided  
20 us a reliable statistical ground to detect genetic effects than nuclear families, twin pair data or  
21 sib-pair data.

22  
23  
24 We report the association of important correlates and significant heritability estimates of the  
25 MetS and its components among JHS AA families. Our data suggests inclusion of biomarkers  
26 like adiponectin and homocysteine to improve early identification of MetS. We have  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 demonstrated significant heritability estimates for the metabolic syndrome itself, and also for  
4  
5 its individual components. The results strongly encourage efforts to identify the underlying  
6  
7 susceptibility genes for this syndrome in AA. Further exploration of the genetic and  
8  
9 environmental factors of the MetS among AAs will lead to a more comprehensive  
10  
11 understanding and better therapeutic options for the syndrome, and ultimately lead to improved  
12  
13 cardiovascular health.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Acknowledgments:** This research was supported by the Intramural Research Program of the National Institutes of Health. The Jackson Heart Study is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. We would like to thank the Jackson Heart Study participants and the staff for their important contributions to the study of determinants of health in African Americans.

**Contributorship statement:** SKD and RJK conceptualized the study. RJK and RX completed the main data analysis. RJK and SKD prepared the manuscript. SYG, PC and MS contributed to the study design, interpretation of data, and the preparation of manuscript. All authors read and approved the final manuscript.

**Conflicts of interest:** The authors declare no conflicts of interest.

**Ethics approval:** University of Mississippi Medical Center Institutional Review Board and National Human Genome Research Institute Institutional Review Board

**Data sharing statement:** No additional data available

## References

1. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. *J Diabetes*. 2010;2(3):180-93.
2. Bhargava A. A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study. *Popul Health Metr*. 2003;1(1):3.
3. Carnethon MR, Loria CM, Hill JO, et al. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. *Diabetes Care*. 2004;27(11):2707-15.
4. Sabo RT, Lu Z, Deng X, et al. Parental and offspring associations of the metabolic syndrome in the Fels Longitudinal Study. *Am J Clin Nutr*. 2012;96(3):461-6.
5. Feng Y, Zang T, Xu X. Familial aggregation of metabolic syndrome and its components in a large Chinese population. *Obesity (Silver Spring)*. 2008;16(1):125-9.
6. Santos DM, Katzmarzyk PT, Tregouet DA, et al. Familial aggregation of metabolic syndrome indicators in portuguese families. *Biomed Res Int*. 2013;2013(314823).
7. Bosy-Westphal A, Onur S, Geisler C, et al. Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: the Kiel obesity prevention study. *Int J Obes*. 2007;31(5):784-90.
8. Groop L, Forsblom C, Lehtovirta M, et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. *Diabetes*. 1996;45(11):1585-93.
9. Freeman MS, Mansfield MW, Barrett JH, et al. Heritability of features of the insulin resistance syndrome in a community-based study of healthy families. *Diabet Med*. 2002;19(12):994-9.
10. Bellia A, Giardina E, Lauro D, et al. "The Linosa Study": epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. *Nutr Metab Cardiovasc Dis*. 2009;19(7):455-61.
11. Henneman P, Aulchenko YS, Frants RR, et al. Prevalence and heritability of the metabolic syndrome and its individual components in a Dutch isolate: the Erasmus Rucphen Family study. *J Med Genet*. 2008;45(9):572-7.
12. Lin HF, Boden-Albala B, Juo SH, et al. Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. *Diabetologia*. 2005;48(10):2006-12.
13. Bayoumi RA, Al-Yahyaee SA, Albarwani SA, et al. Heritability of determinants of the metabolic syndrome among healthy Arabs of the Oman family study. *Obesity (Silver Spring)*. 2007;15(3):551-6.
14. Vattikuti S, Guo J, Chow CC. Heritability and genetic correlations explained by common SNPs for metabolic syndrome traits. *PLoS Genet*. 2012;8(3):29.
15. Luke A, Guo X, Adeyemo AA, et al. Heritability of obesity-related traits among Nigerians, Jamaicans and US black people. *Int J Obes Relat Metab Disord*. 2001;25(7):1034-41.
16. Iliadou A, Snieder H, Wang X, et al. Heritabilities of lipids in young European American and African American twins. *Twin Res Hum Genet*. 2005;8(5):492-8.
17. Price RA, Reed DR, Guido NJ. Resemblance for body mass index in families of obese African American and European American women. *Obes Res*. 2000;8(5):360-6.
18. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. *Circulation*. 2013;127(1):e6-e245.
19. van Dongen J, Willemsen G, Chen WM, et al. Heritability of metabolic syndrome traits in a large population-based sample. *J Lipid Res*. 2013;54(10):2914-23.

- 1
- 2
- 3
- 4 20. Taylor HA, Jr., Wilson JG, Jones DW, et al. Toward resolution of cardiovascular health disparities
- 5 in African Americans: design and methods of the Jackson Heart Study. *Ethn Dis.* 2005;15(4 Suppl
- 6 6):4-17.
- 7
- 8 21. Wilson JG, Rotimi CN, Ekunwe L, et al. Study design for genetic analysis in the Jackson Heart
- 9 Study. *Ethn Dis.* 2005;15(4 Suppl 6):30-37.
- 10
- 11 22. Taylor HA, Jr. The Jackson Heart Study: an overview. *Ethn Dis.* 2005;15(4 Suppl 6):1-3.
- 12
- 13 23. Carpenter MA, Crow R, Steffes M, et al. Laboratory, reading center, and coordinating center
- 14 data management methods in the Jackson Heart Study. *Am J Med Sci.* 2004;328(3):131-44.
- 15
- 16 24. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP)
- 17 Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult
- 18 Treatment Panel III). *Jama.* 2001;285(19):2486-97.
- 19
- 20 25. Grundy SM, Brewer HB, Jr., Cleeman JI, et al. Definition of metabolic syndrome: report of the
- 21 National Heart, Lung, and Blood Institute/American Heart Association conference on scientific
- 22 issues related to definition. *Arterioscler Thromb Vasc Biol.* 2004;24(2):e13-8.
- 23
- 24 26. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc Behav.*
- 25 1983;24(4):385-96.
- 26
- 27 27. Dubbert PM, Carithers T, Ainsworth BE, et al. Physical activity assessment methods in the
- 28 Jackson Heart Study. *Ethn Dis.* 2005;15(4 Suppl 6):56-61.
- 29
- 30 28. Szabo de Edelenyi F, Goumidi L, Bertrais S, et al. Prediction of the metabolic syndrome status
- 31 based on dietary and genetic parameters, using Random Forest. *Genes Nutr.* 2008;3(3-4):173-6.
- 32
- 33 29. Duggirala R, Williams JT, Williams-Blangero S, et al. A variance component approach to
- 34 dichotomous trait linkage analysis using a threshold model. *Genet Epidemiol.* 1997;14(6):987-92.
- 35
- 36 30. Metelskaya VA, Shkolnikova MA, Shalnova SA, et al. Prevalence, components, and correlates of
- 37 metabolic syndrome (MetS) among elderly Muscovites. *Arch Gerontol Geriatr.* 2012;55(2):231-7.
- 38
- 39 31. Mokan M, Galajda P, Pridavkova D, et al. Prevalence of diabetes mellitus and metabolic
- 40 syndrome in Slovakia. *Diabetes Res Clin Pract.* 2008;81(2):238-42.
- 41
- 42 32. Cankurtaran M, Halil M, Yavuz BB, et al. Prevalence and correlates of metabolic syndrome (MS)
- 43 in older adults. *Arch Gerontol Geriatr.* 2006;42(1):35-45.
- 44
- 45 33. Luepker RV, Rosamond WD, Murphy R, et al. Socioeconomic status and coronary heart disease
- 46 risk factor trends. The Minnesota Heart Survey. *Circulation.* 1993;88(5 Pt 1):2172-9.
- 47
- 48 34. Mackenbach JP, Stirbu I, Roskam AJ, et al. Socioeconomic inequalities in health in 22 European
- 49 countries. *N Engl J Med.* 2008;358(23):2468-81.
- 50
- 51 35. Brunner EJ, Marmot MG, Nanchahal K, et al. Social inequality in coronary risk: central obesity
- 52 and the metabolic syndrome. Evidence from the Whitehall II study. *Diabetologia.*
- 53 1997;40(11):1341-9.
- 54
- 55 36. Berlin I, Lin S, Lima JA, et al. Smoking Status and Metabolic Syndrome in the Multi-Ethnic Study
- 56 of Atherosclerosis. A cross-sectional study. *Tob Induc Dis.* 2012;10(1):1617-9625.
- 57
- 58 37. Sun K, Liu J, Ning G. Active smoking and risk of metabolic syndrome: a meta-analysis of
- 59 prospective studies. *PLoS One.* 2012;7(10):17.
- 60
- 61 38. Akbartabartoori M, Lean MEJ, Hankey CR. Relationships between cigarette smoking, body size
- 62 and body shape. *Int J Obes Relat Metab Disord.* 2004;29(2):236-43.
- 63
- 64 39. Filozof C, Fernandez Pinilla MC, Fernandez-Cruz A. Smoking cessation and weight gain. *Obes Rev.*
- 65 2004;5(2):95-103.
- 66
- 67 40. Poulsen P, Vaag A, Kyvik K, et al. Genetic versus environmental aetiology of the metabolic
- 68 syndrome among male and female twins. *Diabetologia.* 2001;44(5):537-43.
- 69
- 70 41. Monda KL, North KE, Hunt SC, et al. The genetics of obesity and the metabolic syndrome. *Endocr*
- 71 *Metab Immune Disord Drug Targets.* 2010;10(2):86-108.

- 1
- 2
- 3
- 4 42. Kristiansson K, Perola M, Tikkanen E, et al. Genome-Wide Screen for Metabolic Syndrome
- 5 Susceptibility Loci Reveals Strong Lipid Gene Contribution But No Evidence for Common Genetic
- 6 Basis for Clustering of Metabolic Syndrome Traits. *Circulation: Cardiovascular Genetics*.
- 7 2012;5(2):242-49.
- 8 43. Joy T, Lahiry P, Pollex RL, et al. Genetics of metabolic syndrome. *Curr Diab Rep*. 2008;8(2):141-8.
- 9 44. Povel CM, Boer JM, Reiling E, et al. Genetic variants and the metabolic syndrome: a systematic
- 10 review. *Obes Rev*. 2011;12(11):952-67.
- 11 45. Lyssenko V, Sjögren M, Almgren P, et al. Genetic prediction of the metabolic syndrome. *Diabetes*
- 12 *& Metabolic Syndrome: Clinical Research & Reviews*. 2008;2(4):245-52.
- 13 46. Kim JY, Ahn SV, Yoon JH, et al. Prospective study of serum adiponectin and incident metabolic
- 14 syndrome: the ARIRANG study. *Diabetes Care*. 2013;36(6):1547-53.
- 15 47. Juonala M, Saarikoski LA, Viikari JS, et al. A longitudinal analysis on associations of adiponectin
- 16 levels with metabolic syndrome and carotid artery intima-media thickness. The Cardiovascular
- 17 Risk in Young Finns Study. *Atherosclerosis*. 2011;217(1):234-9.
- 18 48. Barazzoni R, Silva V, Singer P. Clinical biomarkers in metabolic syndrome. *Nutr Clin Pract*.
- 19 2014;29(2):215-21.
- 20 49. Hajer GR, van der Graaf Y, Olijhoek JK, et al. Levels of homocysteine are increased in metabolic
- 21 syndrome patients but are not associated with an increased cardiovascular risk, in contrast to
- 22 patients without the metabolic syndrome. *Heart*. 2007;93(2):216-20.
- 23 50. Esteghamati A, Hafezi-Nejad N, Zandieh A, et al. Homocysteine and metabolic syndrome: From
- 24 clustering to additional utility in prediction of coronary heart disease. *Journal of Cardiology*. 0)
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
√ <b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
√ <b>Introduction</b>		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
√ <b>Methods</b>		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses
√ <b>Results</b>		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

<b>√Discussion</b>		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
<b>√Other information</b>		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Prevalence, Associated Factors and the Heritability of Metabolic Syndrome and its Individual Components in African Americans: The Jackson Heart Study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2015-008675.R2
Article Type:	Research
Date Submitted by the Author:	12-Aug-2015
Complete List of Authors:	Khan, Rumana; National Institutes of Health, National Human Genome Research Institute Gebreab, Samson; National Institutes of Health, National Human Genome Research Institute Sims, Mario; University of Mississippi Medical Center, Department of Internal Medicine Crespo, Pia; National Institutes of Health, National Human Genome Research Institute Xu, Ruihua; National Institutes of Health, National Human Genome Research Institute Davis, Sharon; National Institutes of Health, National Human Genome Research Institute
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Public health
Keywords:	Metabolic Syndrome, African Americans, Heritability

SCHOLARONE™  
Manuscripts

**Title page:****Title: Prevalence, Associated Factors and the Heritability of Metabolic Syndrome and its Individual Components in African Americans: The Jackson Heart Study****Corresponding author:**

Rumana J Khan

Cardiovascular Section

Genomics of Metabolic, Cardiovascular and Inflammatory Disease Branch, Social Epidemiology

Research Unit, National Human Genome Research Institute, 10 Center Drive, Room 7N316

MSC 1644, Bethesda, MD 20892

e-mail address: rumana.khan@nih.gov

Main: 301-451-2447

Direct: 301-451-2127

Fax: 301-480-0063

**Author names and affiliations****Rumana J Khan, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,

National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,

USA.

**Samson Y Gebreab, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,  
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,  
USA.

**Mario Sims, PhD**

Division of Hypertension, Department of Internal Medicine, University of Mississippi Medical  
Center, Jackson, Mississippi, USA

**Pia R Crespo, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,  
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,  
USA.

**Ruihua Xu, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,  
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,  
USA.

**Sharon K Davis, PhD**

Cardiovascular Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch,  
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,  
USA.

**Keywords:** Metabolic Syndrome, African Americans, Heritability, Associated factors

**Word count:**

The total word count of text: 2965

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objective:** Both environmental and genetic factors play important roles in development of metabolic syndrome (MetS). Studies about its associated factors and genetic contribution in African Americans (AA) are sparse. Our aim was to report the prevalence, associated factors and heritability estimates of MetS and its components in AA men and women.

**Participants and setting:** Data of this cross-sectional study comes from large and community based Jackson Heart Study (JHS). We analyzed a total of 5227 participants, of which 1636 from 281 families were part of the family study subset of JHS.

**Methods:** Participants were classified as having the MetS according to the Adult Treatment Panel III criteria. Multiple logistic regression analysis was performed to isolate independently associated factors of MetS (n=5227). Heritability was estimated from the family study subset using variance component methods (n=1636).

**Results:** About 27% of men and 40% of women had MetS. For men, associated factors with having MetS were older age, lower physical activity, higher body mass index, higher homocysteine and adiponectin level ( $p<0.05$  for all). For women, in addition to all these, lower education, current smoking, and higher stress were also significant ( $p<0.05$  for all). After adjusting for covariates, the heritability of MetS was 32% ( $p<0.001$ ). Heritability ranged from 14 to 45% among its individual components. Relatively higher heritability was estimated for waist circumference (45%), high density lipoprotein-cholesterol (43%) and triglycerides (42%). Heritability of systolic blood pressure (BP), diastolic BP, and fasting blood glucose were 16%, 15%, and 14%, respectively.

**Conclusion:** Stress and low education were associated with having MetS in AA women, but not in men. Higher heritability estimates for lipids and waist circumference supports the hypothesis

1  
2  
3 of lipid metabolism playing the central role in the development of MetS and encourages  
4  
5 additional efforts to identify the underlying susceptibility genes for this syndrome in AA.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## Strengths and limitations of this study

- African American community disproportionately suffers from metabolic syndrome, but relatively little is known about the genetic contribution and the environmental influence of this syndrome among African Americans.
- Using the data from large, community-based Jackson Heart study, this study showed a high prevalence of metabolic syndrome, and reported the associated factors and heritability estimates of metabolic syndrome and its components in African Americans.
- We are not aware of any published data that explored these issues among African American from such a big setting. The large sample size also provided a reliable statistical ground to detect heritability estimates than nuclear families, twin pair data or sib-pair data.
- Potential limitations of this study included the cross-sectional observational design, which could only confirm the associations of the factors with metabolic syndrome, but not the causality, and the absence of information on shared environmental factors like childhood environment and neighborhood factors, which might slightly overestimate the heritability results.
- This study encourages additional efforts to identify the underlying susceptibility genes for metabolic syndrome among African Americans.

## BACKGROUND

Metabolic syndrome (MetS) is a clustering of different interrelated cardio-metabolic risk factors including obesity, elevated blood pressure (BP), dyslipidemia, and impaired fasting plasma glucose (IFG). These risk factors often occur together and increases cardiovascular disease (CVD) deaths almost by three to four fold.<sup>1,2</sup> As MetS is the combined effect of more than one risk factor, the etiology of the MetS is complex. Factors like lifestyle, gender, ethnicity, socioeconomic status, psychosocial factors and some inflammatory markers play key roles in the pathogenesis of MetS.<sup>1-3</sup> Findings also suggest that MetS clusters in families<sup>4-8</sup> and has reasonable heritability, which is defined as the proportion of phenotypic variance in a trait that is attributable to the additive effects of genes.<sup>9-17</sup> Thus, the interplay of both environmental and genetic factors makes MetS a multifactorial disorder.

Though the pathogenesis, diagnosis and the treatment of MetS remain complex because of its multifactorial nature, the construct MetS is an important risk-assessment method for early detection and early intervention of CVD. In spite of steady decline in CVD mortality during recent decades, CVD is still the leading cause of death in all Americans, and is highly prevalent in persons of African ancestry.<sup>18</sup> It is important to note that the majority of studies that explored the associated factors and quantified the heritability of MetS almost exclusively involved Caucasians.<sup>10-14,19</sup> Relatively little is known about these issues among adult African American (AA) population.<sup>15-17</sup> Using the Jackson Heart Study (JHS) data, the objective of this cross-sectional study was to report the prevalence, risk factors and heritability estimates of MetS and its components in AA men and women.

## METHODS

### Data Source

Data of this analysis comes from large and community based JHS, which comprises 5301 adult AA enrolled between September 2000 and March 2004 residing in Jackson, Mississippi, metropolitan area.<sup>20</sup> About 24% of 5301 participated in the JHS family study component.<sup>21</sup> The family study component of JHS contained 1st degree (parent-offspring and siblings), 2nd degree (grandparent-grandchild, avuncular, half-siblings) and 3rd degree or more distant (great grandparent-grandchild, grand avuncular, half avuncular, first cousins, half first cousins, second cousins) family members. The JHS was approved by the University of Mississippi Medical Center Institutional Review Board, and the participants gave written informed consent. Details of the study design and data collection methods are described elsewhere.<sup>21, 22</sup> The current study data were obtained from the baseline clinic visit during 2000-2004. After excluding 74 participants who didn't have information on their MetS status, the current analysis had a total of 5227 participants, of which 1636 from 281 families contributed to the heritability analyses.

### Measures

We collected information on participant's waist circumference (WC), systolic BP (SBP) and diastolic BP (DBP), fasting plasma glucose (FPG), fasting triglyceride, and plasma high-density lipoprotein cholesterol (HDL-C). Two measures of the waist at the level of the umbilicus and in the upright position were averaged to calculate WC. Sitting BP was measured twice at 5-min intervals with standardized Hawksley random-zero sphygmomanometer, and the

1  
2  
3 average of two measurements was used. Fasting blood samples were collected according to  
4  
5 standardized protocols, and the assessments of FPG and lipids were processed at the Central  
6  
7 Laboratory, University of Minnesota.<sup>23</sup> Respondents were asked about their medication usage  
8  
9 for hypertension, diabetes mellitus and high lipid levels. Individuals were classified as having  
10  
11 MetS if they had at least three of the following five components: (1) large WC or abdominal  
12  
13 obesity (> 102 cm for men and > 88 cm for women); (2) hypertriglyceridemia (fasting plasma  
14  
15 triglyceride concentration  $\geq$  150 mg/dL or on drug treatment); (3) low HDL-C levels (< 40  
16  
17 mg/dL for men and < 50 mg/dL in women or on drug treatment); (4) elevated BP ( $\geq$  130 mm  
18  
19 Hg SBP or  $\geq$  85 mm Hg DBP or on drug treatment); or, (5) IFG ( $\geq$  110 mg/dL or on drug  
20  
21 treatment).<sup>24, 25</sup>  
22  
23  
24  
25  
26  
27  
28

29 Data about socio-demographic (age, sex, and education), the psychosocial (stress) and lifestyle  
30  
31 (physical activity, smoking status, and alcohol consumption) variables were also collected. Age  
32  
33 was classified as: 20-39, 40-59, 60-79 and 80 years and above. Education status was self-  
34  
35 reported and was divided into three categories (less than high school, high school/GED/ some  
36  
37 college and college/associate degree or higher, where less than high school was the referent).  
38  
39 Stress level was obtained from The Global Perceived Stress Scale, an 8-item questionnaire that  
40  
41 measures the severity of chronic stress experienced over a prior period of twelve months.<sup>26</sup> The  
42  
43 physical activity index composite score was calculated as the sum of four different domains of  
44  
45 physical activity: active living, work, home and garden, and sport and exercise indices.<sup>27</sup>  
46  
47  
48 Smoking status was classified as never (referent), current, and former. Alcohol consumption  
49  
50 status was defined as “yes” if they currently consumed alcoholic beverages and “no” (referent)  
51  
52 if they had stopped drinking for more than a year, or if they never consumed alcohol.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Information on clinical factors like body mass index or BMI (weight in kg divided by height in  
4  
5 meter square), C-reactive protein or CRP (mg/dL), serum adiponectin (mg/dL), and serum  
6  
7 homocysteine (umol/L) were also obtained.<sup>23</sup>  
8  
9

## 10 11 12 **Analysis**

13  
14  
15 Data from the full cohort (n= 5227) were used to explore the risk factors of MetS. Socio-  
16  
17 demographic, psychosocial, lifestyle and clinical characteristics of participants were compared  
18  
19 by gender and MetS status using the chi-square or independent t-test. The primary outcome  
20  
21 measure for this analysis was the presence of MetS, evaluated as a dichotomous variable.  
22  
23

24  
25 Logistic regression analysis was used to examine the association between each independent  
26  
27 variable (age, education level, stress level, physical activity score, smoking status, alcohol  
28  
29 consumption status, BMI, CRP, fasting total cholesterol, serum concentration of adiponectin,  
30  
31 and serum homocysteine) with the outcome of MetS. A multiple logistic regression model was  
32  
33 fitted including all variables to isolate the statistically significant predictors of MetS. The  
34  
35 regression analysis was conducted using SAS software, Version 9.3.<sup>28</sup>  
36  
37  
38  
39  
40

## 41 **Heritability Analysis**

42  
43 After checking the pedigree data for inconsistencies a total of 1636 individuals from 281  
44  
45 families were analyzed to calculate the heritability estimates by variance component methods  
46  
47 using SOLAR (Sequential Oligogenic Linkage Analysis Routines) software package to quantify  
48  
49 the proportion of the variance in MetS and in its individual components that was attributable to  
50  
51 the additive effects of genes.<sup>29</sup> We estimated the heritability of individual MetS components  
52  
53 (treated as continuous variable) including WC, SBP, DBP, FPG, fasting triglyceride, and  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 plasma HDL-C with adjustment for age, education level, physical activity index composite  
4 score, smoking status, alcohol consumption status and respective medication usage. Log  
5 transformed values of FPG and triglycerides were used due to deviation from normal  
6 distribution. Heritabilities were calculated using a standard quantitative genetic variance-  
7 components model implemented in SOLAR.<sup>29</sup> This approach uses the maximum-likelihood  
8 estimation to a mixed-effects model that incorporates fixed covariate effects, additive genetic  
9 effects and residual error. The heritability of MetS (discrete variable) was analyzed by a  
10 threshold model in SOLAR. The method assumed that an individual belonged to a specific  
11 affected status if an underlying genetically determined risk exceeded a certain threshold.<sup>30</sup>  
12  
13 For all the analyses, significance level set at  $p < 0.05$  were used.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

## 30 RESULTS

31  
32 Table 1 presents the characteristics of JHS participants. Of the 5227 individuals, 1909 (36.52%,  
33 mean age 53.93 years and standard deviation or SD=12.93) were men and 3318 (63.48%, mean  
34 age 55.30  $\pm$ 12.76) were women. Education levels were similar for men and women. About 40%  
35 of men and women had college level education or beyond. A clear gender difference however,  
36 was found for alcohol use and smoking, with women being far less likely than men to consume  
37 alcohol and smoke cigarettes ( $p < 0.001$ ). Women reported greater levels of stress, but lower  
38 level of physical activity than men ( $p < 0.001$ ). Women also had higher BMI, CRP, adiponectin,  
39 and lower homocysteine level than men ( $p < 0.001$  for all). Table 1 also shows the prevalence of  
40 MetS and its individual components among the JHS participants. About 27.34% of the men and  
41 38.94% of the women had MetS ( $p < 0.001$ ). In terms of individual components, women had  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

higher abdominal obesity (75.70% versus 41.03%,  $p < 0.001$ ) and IFG (22.45% versus 19.64%,  $p < 0.001$ ), but lower hypertriglyceridemia (13.23% versus 18.39%,  $p < 0.001$ ) than men.

**Table 1: Characteristics of Participants of the Jackson Heart Study by Gender (N=5227)**

	<b>Total<sup>a</sup> n=5227</b>	<b>Men<sup>a</sup> n=1909</b>	<b>Women<sup>a</sup> n=3318</b>	<b>P value<sup>b</sup></b>
<b>Age in years</b>	54.87 (12.84)	53.93 (12.93)	55.30 (12.76)	0.0002
<b>Education level</b>				
Less than high school	18.4	18.73	17.88	
High school/GED or some college	42.2	42.82	41.83	
College/associate degree or higher	39.4	38.45	40.29	0.4094
<b>Smoking Status</b>				
Never	67.9	56.68	74.59	
Former	18.9	25.33	15.30	
Current	13.2	17.99	10.11	<.0001
<b>Alcohol drinking status</b>				
Yes	47.2	58.92	38.41	
No		41.08	61.59	<.0001
<b>Total Physical Activity Score<sup>c</sup></b>	8.31 (2.61)	8.64 (2.63)	8.16 (2.58)	<.0001
<b>Global Stress Total Score<sup>d</sup></b>	5.14 (4.21)	4.50 (4.20)	5.52 (4.45)	<.0001
<b>Body mass index (weight in kg/height in squared meter)</b>	31.75 (7.24)	29.83±6.14	32.86 (7.59)	<.0001
<b>High Sensitivity C-Reactive Protein in mg/dL</b>	0.51 (0.87)	0.35 (0.96)	0.60 (0.85)	<.0001
<b>Homocysteine in umol/L</b>	9.44 (4.68)	10.17 (3.56)	9.00 (5.20)	<.0001
<b>Adiponectin level in µg/mL</b>	5.41 (4.16)	4.15 (3.41)	6.15 (4.57)	<.0001
<b>Abdominal obesity<sup>e</sup></b>	62.9	41.03	75.70	<.0001
<b>Hypertriglyceridemia</b>	16.5	18.39	13.23	<.0001
<b>Low HDL-C<sup>g</sup></b>	37.2	33.01	39.55	<.0001
<b>Elevated blood Pressure<sup>h</sup></b>	70.3	69.62	70.58	0.4616
<b>impaired fasting glucose<sup>i</sup></b>	22.4	19.64	22.45	0.0171
<b>Metabolic syndrome<sup>k</sup></b>	34.4	27.34	38.94	<.0001

<sup>a</sup>Data presented as mean (SD) or percentage of subjects

<sup>b</sup>Independent t-test or Chi-square test comparing characteristics of men and women;

<sup>c</sup>sum of the four different domains of physical activity;

<sup>d</sup>sum of 8 item questionnaire that measures the severity of chronic stress experienced over a prior period of twelve months;

<sup>e</sup>waist circumference > 102 cm for men and > 88 cm for women

<sup>f</sup>fasting plasma triglyceride concentration ≥ 150 mg/dL or on drug treatment

<sup>g</sup>HDL cholesterol levels <40 mg/dL for men and < 50 mg/dL in women or on drug treatment

<sup>h</sup>Blood pressure ≥ 130 mm Hg systolic or ≥ 85 mm Hg diastolic or on drug treatment

<sup>i</sup>fasting glucose ≥ 110 mg/dL or on drug treatment

<sup>k</sup> Metabolic Syndrome defined as having at least three of the following five components: (1) abdominal obesity; (2) hypertriglyceridemia; (3) low HDL cholesterol levels; (4) elevated blood; (5) impaired fasting glucose

Table 2 shows the descriptive characteristics of participants by MetS status. Those who had MetS were older, less educated, less likely to smoke, less likely to consume alcohol, and less physically active ( $p < 0.001$  for all). They also had higher BMI, higher CRP and higher homocysteine level; but lower adiponectin concentration ( $p < 0.001$  for all). The unadjusted and the adjusted relationships of MetS with these features are displayed in Table 3. After adjustment, older age remained significant for both men and women. Notably, the trend of having MetS with increasing age was clearer for women than for men. Education was only significant for women, and not for men. Women who went to high school had 24% (adjusted odds ratio or AOR: 0.76; 95% confidence interval or CI: 0.59-0.97) decreased odds of having MetS compared to those who had the lowest education level. Like education, higher stress level was also a significant factor for women only (AOR: 1.02; 95% CI: 1.01-1.04). Physical activity decreased the odds of having MetS for both sexes, but alcohol consumption was associated with 26% decreased odds (AOR: 0.74; 95% CI: 0.61-0.90) of MetS for women only. Relationship between smoking and MetS was different for men and women. While current smoking only predicted women's MetS (AOR: 1.43; 95% CI: 1.07-1.91), former smoking had significant association with men's MetS (AOR: 1.54; 95% CI: 1.14-2.08). Biomedical risk factors such as increased BMI (AOR: 1.18; 95% CI: 1.15-1.21 for men and AOR: 1.08; 95% CI: 1.07-1.10 for women), increased serum homocysteine (AOR: 1.05; 95% CI: 1.02-1.09 for men and AOR: 1.06; 95% CI: 1.03-1.09 for women) and decreased serum adiponectin (AOR: 0.90; 95% CI: 0.85-0.95 for men and AOR: 0.90; 95% CI: 0.87-0.92 for women) were associated with increased odds of having MetS for both sexes.



**Table 2: Characteristics of Jackson Heart Study Participants by metabolic syndrome status (N=5227)**

	<b>Metabolic Syndrome<sup>a</sup> (n=1814)</b>	<b>No Metabolic Syndrome<sup>a</sup> (n=3413)</b>	<b>P value<sup>b</sup></b>
<b>Age in years</b>	58.04 (11.43)	53.07 (13.21)	<.0001
<b>Gender of Participant</b>			
Men	28.78	40.46	
Women	71.22	59.36	<.0001
<b>Education level</b>			
Less than high school	23.32	15.46	
High school/GED or some college	41.94	42.33	
College/associate degree or higher	34.74	42.21	<.0001
<b>Smoking Status</b>			
Never	66.17	69.05	
Former	21.59	17.56	
Current	12.24	13.39	0.0017
<b>Alcohol drinking status</b>			
Yes	37.01	50.63	
No	62.99	49.37	<.0001
<b>Total Physical Activity Score<sup>c</sup></b>	7.74 (2.56)	8.65 (2.57)	<.0001
<b>Global Stress Total Score<sup>d</sup></b>	5.11 (4.42)	5.17 (4.37)	0.6251
<b>Body mass index (weight in kg/height in squared meter)</b>	34.87 (6.92)	30.10 (6.86)	<.0001
<b>High Sensitivity C-Reactive Protein in mg/dL</b>	0.65 (1.13 )	0.44 (0.74)	<.0001
<b>Homocysteine: The concentration of homocysteine in umol/L</b>	9.94 (6.37)	9.15 (3.44)	<.0001
<b>Serum concentration of adiponectin in µg/mL</b>	4.72 (4.02)	5.79 (4.38)	<.0001

<sup>a</sup>Data presented as mean (SD) or percentage of subjects

<sup>b</sup>Independent t-test or Chi-square test;

<sup>c</sup>sum of the four different domains of physical activity;

<sup>d</sup>sum of 8 item questionnaire that measures the severity of chronic stress experienced over a prior period of twelve months;

**Table 3: Association between selected factors and prevalence of metabolic Syndrome among Jackson Heart Study Participants (n=5227)**

	Metabolic Syndrome Odds Ratio (95% CI)			
	Men (n=1909)		Women (n=3318)	
	Unadjusted <sup>a</sup>	Adjusted <sup>a</sup>	Unadjusted <sup>a</sup>	Adjusted <sup>a</sup>
<b>Age</b>	Reference Level		Reference Level	
20-39	Reference Level		Reference Level	
40-59	1.34(0.96-1.86)	1.55 (1.02-2.35)	2.44(1.84-3.23)	2.79 (2.00 -3.87)
60-79	1.69(1.20-2.38)	2.17 (1.34-3.51)	4.69(3.54-6.22)	5.50 (3.81-7.93)
80 and above	0.88(0.28-2.71)	2.18 (0.60-8.00)	3.43(1.89-6.24)	5.06 (2.34-10.96)
<b>Education</b>	Reference Level		Reference Level	
Less than High school	Reference Level		Reference Level	
High school or some College	0.95(0.72-1.25)	1.20 (0.83-1.74)	0.53(0.44-0.65)	0.76 (0.59- 0.97)
College degree or higher	0.79(0.60-1.05)	1.05 (0.72 1.55)	0.44(0.36-0.53)	0.82 (0.63-1.07)
<b>Smoking Status</b>	Reference Level		Reference Level	
Never	Reference Level		Reference Level	
Former	1.47(1.16-1.85)	1.54 (1.14-2.08)	1.39(1.15-1.69)	1.20 (0.95-1.52)
Current	0.92(0.69-1.22)	1.29 (0.89-1.86)	1.20(0.95-1.51)	1.43 (1.07-1.91)
<b>Alcohol drinking</b>	Reference Level		Reference Level	
No	Reference Level		Reference Level	
Yes	0.72(0.59-0.88)	0.85 (0.66-1.11)	0.57(0.49-0.66)	0.74 (0.61-0.90)
<b>Physical Activity<sup>b</sup></b>	0.90(0.86-0.94)	0.93 (0.88- 0.98)	0.86(0.84-0.89)	0.94 (0.91-0.98)
<b>Global Stress<sup>c</sup></b>	1.01(0.98-1.03)	1.02 (0.99-1.06)	0.98(0.97-1.00)	1.02 (1.01- 1.04)
<b>Body mass index</b>	1.18(1.15-1.20)	1.18 (1.15-1.21)	1.08(1.07-1.09)	1.08 (1.07-1.10)
<b>C-Reactive Protein in mg/dL</b>	1.36(1.15-1.60)	1.10 (0.96- 1.26)	1.29(1.18-1.41)	0.99 (0.89-1.09)
<b>Homocysteine in umol/L</b>	1.04(1.01-1.07)	1.05 (1.02 1.09)	1.07(1.05-1.10)	1.06(1.03-1.09)
<b>Adiponectin in µg/mL</b>	0.89(0.85-0.92)	0.90 (0.85-0.95)	0.91(0.90-0.93)	0.90 (0.87-0.92)

Metabolic Syndrome defined as having at least three of the following five components: (1) abdominal obesity or large waist circumference (> 102 cm for men and > 88 cm for women); (2) hypertriglyceridemia (fasting plasma triglyceride concentration  $\geq$  150 mg/dL or on drug treatment); (3) low HDL cholesterol levels (< 40 mg/dL for men and < 50 mg/dL in women or on drug treatment); (4) elevated blood pressure ( $\geq$  130 mm Hg systolic or  $\geq$  85 mm Hg diastolic or on drug treatment); or, (5) IFG or impaired fasting glucose (110 mg/dL or on drug treatment)

<sup>a</sup>Analysis done using simple and multiple logistic regression. The multivariate models are adjusted for for all other variables in the table.

<sup>b</sup>sum of the four different domains of physical activity;

1  
2  
3 <sup>c</sup>sum of 8 item questionnaire that measures the severity of chronic stress experienced over a prior period of twelve  
4 months;  
5  
6  
7

8 Table 4 illustrates the heritability estimates along with the proportion of variation explained by  
9 covariates ( $\sigma_e^2$ ) of MetS and its individual component in the family study subset (n=1636). All  
10 components of the MetS were significantly correlated with each other except for the pairs of  
11 blood pressure and HDL-C and blood pressure and fasting glucose (results not shown in table).  
12 After accounting for the covariates (except medication), the heritability of MetS was about 32%  
13 ( $p<0.0001$ ,  $\sigma_e^2$ : 10%). The adjusted heritability of individual MetS components ranged from the  
14 lowest of 14% ( $p<0.01$ ,  $\sigma_e^2$ : 33%) for FPG to the highest of 45% ( $p<0.0001$ ,  $\sigma_e^2$ : 8%) for WC  
15 after adjusting for all the covariates. The adjusted estimates of DBP (15%,  $p<0.01$ ,  $\sigma_e^2$ : 9%) and  
16 SBP (16%,  $p<0.001$ ,  $\sigma_e^2$ : 22%) were on the lower end and similar to the estimate of FPG.  
17 Conversely, heritability of triglyceride (42%,  $p<0.001$ ,  $\sigma_e^2$ : 10%) and HDL-C (43%,  $p<0.001$ ,  
18  $\sigma_e^2$ : 11%) was relatively high and similar to the heritability of WC.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 4: Heritability estimates of Metabolic Syndrome and its individual components of Jackson Heart Study Participants (n=1636)**

	Heritability Estimate	Standard error	P value	Proportion of variation explained by covariates
<b>Metabolic Syndrome<sup>a</sup></b>	0.32	0.08	<0.0001	0.10 <sup>e</sup>
<b>Fasting Plasma Glucose<sup>b,c</sup></b>	0.14	0.06	<0.01	0.33 <sup>d</sup>
<b>Waist Circumference<sup>b</sup></b>	0.45	0.06	<0.0001	0.08 <sup>e</sup>
<b>High Density Lipoprotein Cholesterol<sup>b</sup></b>	0.43	0.07	<0.0001	0.11 <sup>d</sup>
<b>Fasting Triglyceride<sup>b,c</sup></b>	0.42	0.05	<0.0001	0.10 <sup>d</sup>
<b>Systolic blood pressure<sup>b</sup></b>	0.16	0.07	<0.001	0.22 <sup>d</sup>
<b>Diastolic blood pressure<sup>b</sup></b>	0.15	0.05	<0.01	0.09 <sup>d</sup>

<sup>a</sup>Treated as discrete trait, and defined as having at least three of the following five components: (1) abdominal obesity or large waist circumference (> 102 cm for men and > 88 cm for women); (2) hypertriglyceridemia (fasting plasma triglyceride concentration  $\geq$  150 mg/dL or on drug treatment); (3) low HDL cholesterol levels (< 40 mg/dL for men and < 50 mg/dL in women or on drug treatment); (4) elevated blood pressure ( $\geq$  130 mm Hg systolic or  $\geq$  85 mm Hg diastolic or on drug treatment); or, (5) IFG or impaired fasting glucose (110 mg/dL or on drug treatment)

<sup>b</sup>Treated as continuous trait

<sup>c</sup>Log transformed

<sup>d</sup> Covariates are age, sex, education, smoking status, alcohol intake, physical activity and respective medication

<sup>e</sup> Covariates are age, sex, education, smoking status, alcohol intake, physical activity

## DISCUSSION

We provide here the epidemiological and heritability data about MetS and its related traits according ATP III criteria among AA. Overall, in our study sample, the prevalence of MetS was higher among women than men. Factors independently associated with having MetS for men were older age, lower physical activity level, higher BMI, higher level of homocysteine and lower level of adiponectin. For women, in addition to older age, lower physical activity level, higher BMI, higher level of homocysteine and lower level of adiponectin, , low education, higher stress, current smoking and alcohol consumption were also significant. The

1  
2  
3 heritability of the MetS was 32% and among its individual components, heritability ranged  
4  
5 from 14% for FPG to 45% for WC.  
6  
7  
8  
9

10 The prevalence of MetS that we found (38.94% of women and 27.34% of men) was almost  
11 identical to a recent estimate from a National Survey, which reported 38.2% of AA women and  
12 25.5% of AA men had MetS.<sup>1</sup> A higher prevalence of MetS in women than in men has been  
13 reported in several other Asian and Eastern European countries, as well as among Hispanic, and  
14 Native Americans.<sup>1, 31-33</sup> However, it is opposite for US Caucasians with higher prevalence in  
15 men.<sup>1</sup> This, together with our finding suggest the possibility of an increased risk of MetS for  
16 women belonging to an economically disadvantaged or a minority population group. The  
17 unfavorable condition of women was also evident from our multivariate analysis, where we  
18 found lower education and stress to be significantly related with MetS for women, but not for  
19 men. While in the industrialized society social class and education are typically inversely  
20 related to different cardio-metabolic risk factors regardless of gender,<sup>34-36</sup> in our study, this was  
21 true only for women, indicating an adverse social environment of our women participants.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 Literature have indicated active smoking to be associated with development of MetS.<sup>37, 38</sup> We  
42 however found, active smoking to be associated with women's MetS only. The lack of  
43 association between current smoking and MetS among men in our study can be partly attributed  
44 to the much discussed inverse association between active smoking and obesity as the smoking  
45 prevalence was higher and abdominal obesity was relatively lower in the men than women in  
46 our analysis.<sup>39</sup> Further, researchers have also found smoking cessation to be frequently  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 followed by weight gain,<sup>40</sup> which explains our observed association between past smoking and  
4  
5 men's MetS.  
6  
7  
8  
9

10 Although lifestyle, physiological and socio-demographic factors play key roles in the  
11 pathogenesis of MetS, there is also strong evidence that the syndrome is inherited.<sup>41-44</sup> We  
12 evaluated the contributions of genetic factors to the phenotypic variability of MetS and its traits  
13 by heritability estimation. According to various studies from different ethnic groups,  
14 heritability of MetS ranges from approximately 19 to 38%.<sup>10-13</sup> A Dutch study estimated a  
15 heritability of 19.2% of MetS in an isolated group of population.<sup>11</sup> A heritability of 24% in a  
16 Caribbean-Hispanic population has been reported by Lin et al.<sup>12</sup> The heritability for the  
17 Caucasian population was about 27% according to large population based study.<sup>10</sup> Bayoumi et  
18 al. reported a heritability of 38% of MetS in healthy Omani Arab families.<sup>13</sup> Besides the genetic  
19 effect itself, which could be different among different studied populations, the discrepancy in  
20 heritability might be attributable to other factors such as different sample sizes, different  
21 structure of pedigrees or covariates included in the analysis. Compared to different ethnic  
22 groups, relatively little information is available on the heritability of MetS in AA population.  
23 The heritability of MetS in our study was 32% after taking into account the contributions of  
24 covariates, like age, sex, alcohol consumption, smoking and physical activity level, suggesting  
25 that more than one-third of the variance in MetS was attributable to the additive effects of  
26 genes in the JHS participants. This estimate is on the higher end of the heritability range  
27 reported so far, which suggests significant genetic influences on clustering of risk factors  
28 among AA.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Reported heritability from different studies for the individual traits ranges from 10% for plasma glucose to 60% for HDL-C.<sup>10-14, 19</sup> Our estimates correspond well with these findings. In the present study, more than 40% of the variance in HDL-C, triglyceride and WC was attributable to genetic effect. Conversely, a moderate but significant heritability were observed for BP and FPG. In different studies as well, HDL-C, obesity and lipid profiles showed the strongest heritability, and BP and FPG had the lowest heritability.<sup>10-14</sup> While for lipid levels and WC genetic influence remains dominant; it seems, for FPG and BP the environmental contribution play a more prominent role, which was apparent by the remarkable covariate effect that was observed for FPG and BP (33% and 22%, respectively) not only in our findings, but also in some other studies.<sup>10, 12</sup> This hypothesis is further supported by some genetic association studies, where investigators have tried to find a unifying pathogenic mechanism for the different MetS components and identify genetic variants contributing to MetS. No such work among AA were found, but a meta-analysis of 4000 Asian and Caucasian participants reviewing 25 genes reported an association between MetS and single nucleotide polymorphisms in the FTO, TCFL72, IL6, APOA5, APOC3 and CETP genes.<sup>45</sup> Another Swedish study found that genetic variants in the PPARG and ADRB1 genes conferred an increased risk of future MetS<sup>46</sup>. All of these genes are mostly involved in lipid metabolism<sup>45, 46</sup>. These evidence indicate that lipid metabolism plays the central role in MetS development; and possibly, genetic impact FPG and BP have a relatively minor role in MetS clusters. Our finding also indirectly supports this view as we found triglyceride, HDL-C and WC to be strongly correlated with one another and a relatively weaker correlation for blood pressure and FPG with other traits. More importantly, we also found higher and similar heritability estimates for triglyceride, HDL-C and WC and relatively lower heritability estimates for BP and FPG,

1  
2  
3 suggesting a possible similarity in genetic mechanism of developing MetS for AA population  
4  
5 with other ethnic groups.  
6  
7  
8  
9

10  
11  
12 Our findings reconfirm that MetS is a complex disease and lifestyle, SES, and genetic  
13 background play important roles in the development of MetS. It was obvious from our study  
14 that social and economic context has disparate impact on women's cardiovascular health and  
15 subsequent policies and health educational programs should be particularly directed towards  
16 women for future CVD risk reduction. As the causes of the MetS are reversible and the  
17 individual components are modifiable, lifestyle change such as increasing physical activity may  
18 reduce the prevalence of MetS in AA people. We found a significant and independent inverse  
19 association between MetS and adiponectin; and a positive association between MetS and  
20 homocysteine. In line with our findings, a number of recent studies also have reported similar  
21 results.<sup>47-51</sup> These findings suggest, monitoring circulating adiponectin and homocysteine level  
22 could provide useful clinical information on risk of developing MetS and provide effective  
23 targets for intervention aimed at modifying lifestyle. However, further studies, including  
24 economic evaluations and prospective studies should investigate whether these markers would  
25 prove useful and cost effective in the early identification of MetS. In the present study we  
26 found considerable heritability of MetS among AA. This provides direct support for performing  
27 genome-wide association studies in this population. Our finding also supports the hypothesis of  
28 lipid metabolism playing the central role in the development of MetS and strongly encourages  
29 additional efforts to identify the underlying susceptibility genes for this syndrome in AA.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Our results should be interpreted within the context of few limitations. We acknowledge that  
4 given our cross-sectional observational design, our study can only confirm the associations of  
5 the factors with MetS; and cannot prove the causality. We also recognize the considerable  
6 disagreement over the definition and diagnostic criteria related to MetS. Of the various  
7 available definitions, we used the ATP III criteria as this is the most widely used definition in  
8 the US<sup>1,24</sup>. It can be, however, argued that some other available definition of MetS could be  
9 equally valid and produce somewhat different result. Though we have accounted for important  
10 individual covariates, our heritability estimates were influenced by shared environmental  
11 factors like childhood environment and neighborhood factors, and thus, our results could be  
12 slightly overestimated. One of the major strengths of our study is, our data although cross-  
13 sectional, comes from a large, community-based AA population, who are vastly understudied  
14 but have high prevalence of metabolic diseases including obesity, diabetes, hypertension and  
15 others. We are not aware of any published data that reported the associated factors and  
16 quantified the heritability of MetS among AA from such a big setting. Further, assessment of  
17 socio-demographic variables in the JHS was performed uniformly and precise techniques were  
18 used to measure all physiological and biochemical values, which makes our findings reliable.  
19 JHS also has a complex and extended pedigree structure with a large sample, which provided  
20 us a reliable statistical ground to detect genetic effects than nuclear families, twin pair data or  
21 sib-pair data.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 We report the association of important correlates and significant heritability estimates of the  
4 MetS and its components among JHS AA families. Our data suggests inclusion of biomarkers  
5 like adiponectin and homocysteine to improve early identification of MetS. We have  
6 demonstrated significant heritability estimates for the metabolic syndrome itself, and also for  
7 its individual components. The results strongly encourage efforts to identify the underlying  
8 susceptibility genes for this syndrome in AA. Further exploration of the genetic and  
9 environmental factors of the MetS among AAs will lead to a more comprehensive  
10 understanding and better therapeutic options for the syndrome, and ultimately lead to improved  
11 cardiovascular health.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Acknowledgments:** This research was supported by the Intramural Research Program of the  
4  
5 National Institutes of Health. The Jackson Heart Study is supported by contracts  
6  
7  
8 HHSN268201300046C, HHSN268201300047C, HHSN268201300048C,  
9  
10 HHSN268201300049C, HHSN268201300050C from the National Heart, Lung, and Blood  
11  
12 Institute and the National Institute on Minority Health and Health Disparities. We would like to  
13  
14 thank the Jackson Heart Study participants and the staff for their important contributions to the  
15  
16 study of determinants of health in African Americans.  
17  
18

19  
20 **Contributorship statement:** SKD and RJK conceptualized the study. RJK and RX completed  
21  
22 the main data analysis. RJK and SKD prepared the manuscript. SYG, PC and MS contributed to  
23  
24 the study design, interpretation of data, and the preparation of manuscript. All authors read and  
25  
26 approved the final manuscript.  
27  
28

29  
30 **Conflicts of interest:** The authors declare no conflicts of interest.  
31

32 **Ethics approval:** University of Mississippi Medical Center Institutional Review Board and  
33  
34 National Human Genome Research Institute Institutional Review Board  
35

36 **Data sharing statement:** No additional data available  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. *J Diabetes*. 2010;2(3):180-93.
2. Bhargava A. A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study. *Popul Health Metr*. 2003;1(1):3.
3. Carnethon MR, Loria CM, Hill JO, et al. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. *Diabetes Care*. 2004;27(11):2707-15.
4. Sabo RT, Lu Z, Deng X, et al. Parental and offspring associations of the metabolic syndrome in the Fels Longitudinal Study. *Am J Clin Nutr*. 2012;96(3):461-6.
5. Feng Y, Zang T, Xu X. Familial aggregation of metabolic syndrome and its components in a large Chinese population. *Obesity (Silver Spring)*. 2008;16(1):125-9.
6. Santos DM, Katzmarzyk PT, Tregouet DA, et al. Familial aggregation of metabolic syndrome indicators in portuguese families. *Biomed Res Int*. 2013;2013(314823).
7. Bosy-Westphal A, Onur S, Geisler C, et al. Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: the Kiel obesity prevention study. *Int J Obes*. 2007;31(5):784-90.
8. Groop L, Forsblom C, Lehtovirta M, et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. *Diabetes*. 1996;45(11):1585-93.
9. Freeman MS, Mansfield MW, Barrett JH, et al. Heritability of features of the insulin resistance syndrome in a community-based study of healthy families. *Diabet Med*. 2002;19(12):994-9.
10. Bellia A, Giardina E, Lauro D, et al. "The Linosa Study": epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. *Nutr Metab Cardiovasc Dis*. 2009;19(7):455-61.
11. Henneman P, Aulchenko YS, Frants RR, et al. Prevalence and heritability of the metabolic syndrome and its individual components in a Dutch isolate: the Erasmus Rucphen Family study. *J Med Genet*. 2008;45(9):572-7.
12. Lin HF, Boden-Albala B, Juo SH, et al. Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. *Diabetologia*. 2005;48(10):2006-12.
13. Bayoumi RA, Al-Yahyaee SA, Albarwani SA, et al. Heritability of determinants of the metabolic syndrome among healthy Arabs of the Oman family study. *Obesity (Silver Spring)*. 2007;15(3):551-6.
14. Vattikuti S, Guo J, Chow CC. Heritability and genetic correlations explained by common SNPs for metabolic syndrome traits. *PLoS Genet*. 2012;8(3):29.
15. Luke A, Guo X, Adeyemo AA, et al. Heritability of obesity-related traits among Nigerians, Jamaicans and US black people. *Int J Obes Relat Metab Disord*. 2001;25(7):1034-41.
16. Iliadou A, Snieder H, Wang X, et al. Heritabilities of lipids in young European American and African American twins. *Twin Res Hum Genet*. 2005;8(5):492-8.
17. Price RA, Reed DR, Guido NJ. Resemblance for body mass index in families of obese African American and European American women. *Obes Res*. 2000;8(5):360-6.
18. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. *Circulation*. 2013;127(1):e6-e245.
19. van Dongen J, Willemsen G, Chen WM, et al. Heritability of metabolic syndrome traits in a large population-based sample. *J Lipid Res*. 2013;54(10):2914-23.

- 1
- 2
- 3
- 4 20. Taylor HA, Jr., Wilson JG, Jones DW, et al. Toward resolution of cardiovascular health disparities
- 5 in African Americans: design and methods of the Jackson Heart Study. *Ethn Dis*. 2005;15(4 Suppl
- 6 6):4-17.
- 7
- 8 21. Wilson JG, Rotimi CN, Ekunwe L, et al. Study design for genetic analysis in the Jackson Heart
- 9 Study. *Ethn Dis*. 2005;15(4 Suppl 6):30-37.
- 10
- 11 22. Taylor HA, Jr. The Jackson Heart Study: an overview. *Ethn Dis*. 2005;15(4 Suppl 6):1-3.
- 12
- 13 23. Carpenter MA, Crow R, Steffes M, et al. Laboratory, reading center, and coordinating center
- 14 data management methods in the Jackson Heart Study. *Am J Med Sci*. 2004;328(3):131-44.
- 15
- 16 24. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP)
- 17 Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult
- 18 Treatment Panel III). *Jama*. 2001;285(19):2486-97.
- 19
- 20 25. Grundy SM, Brewer HB, Jr., Cleeman JI, et al. Definition of metabolic syndrome: report of the
- 21 National Heart, Lung, and Blood Institute/American Heart Association conference on scientific
- 22 issues related to definition. *Arterioscler Thromb Vasc Biol*. 2004;24(2):e13-8.
- 23
- 24 26. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc Behav*.
- 25 1983;24(4):385-96.
- 26
- 27 27. Dubbert PM, Carithers T, Ainsworth BE, et al. Physical activity assessment methods in the
- 28 Jackson Heart Study. *Ethn Dis*. 2005;15(4 Suppl 6):56-61.
- 29
- 30 28. SAS® 9.3, Copyright © 2011. In *SAS Institute Inc*. Cary, NC, USA.
- 31
- 32 29. Szabo de Edelenyi F, Goumidi L, Bertrais S, et al. Prediction of the metabolic syndrome status
- 33 based on dietary and genetic parameters, using Random Forest. *Genes Nutr*. 2008;3(3-4):173-6.
- 34
- 35 30. Duggirala R, Williams JT, Williams-Blangero S, et al. A variance component approach to
- 36 dichotomous trait linkage analysis using a threshold model. *Genet Epidemiol*. 1997;14(6):987-92.
- 37
- 38 31. Metelskaya VA, Shkolnikova MA, Shalnova SA, et al. Prevalence, components, and correlates of
- 39 metabolic syndrome (MetS) among elderly Muscovites. *Arch Gerontol Geriatr*. 2012;55(2):231-7.
- 40
- 41 32. Mokan M, Galajda P, Pridavkova D, et al. Prevalence of diabetes mellitus and metabolic
- 42 syndrome in Slovakia. *Diabetes Res Clin Pract*. 2008;81(2):238-42.
- 43
- 44 33. Cankurtaran M, Halil M, Yavuz BB, et al. Prevalence and correlates of metabolic syndrome (MS)
- 45 in older adults. *Arch Gerontol Geriatr*. 2006;42(1):35-45.
- 46
- 47 34. Luepker RV, Rosamond WD, Murphy R, et al. Socioeconomic status and coronary heart disease
- 48 risk factor trends. The Minnesota Heart Survey. *Circulation*. 1993;88(5 Pt 1):2172-9.
- 49
- 50 35. Mackenbach JP, Stirbu I, Roskam AJ, et al. Socioeconomic inequalities in health in 22 European
- 51 countries. *N Engl J Med*. 2008;358(23):2468-81.
- 52
- 53 36. Brunner EJ, Marmot MG, Nanchahal K, et al. Social inequality in coronary risk: central obesity
- 54 and the metabolic syndrome. Evidence from the Whitehall II study. *Diabetologia*.
- 55 1997;40(11):1341-9.
- 56
- 57 37. Berlin I, Lin S, Lima JA, et al. Smoking Status and Metabolic Syndrome in the Multi-Ethnic Study
- 58 of Atherosclerosis. A cross-sectional study. *Tob Induc Dis*. 2012;10(1):1617-9625.
- 59
- 60 38. Sun K, Liu J, Ning G. Active smoking and risk of metabolic syndrome: a meta-analysis of
- prospective studies. *PLoS One*. 2012;7(10):17.
39. Akbartabartoori M, Lean MEJ, Hankey CR. Relationships between cigarette smoking, body size
- and body shape. *Int J Obes Relat Metab Disord*. 2004;29(2):236-43.
40. Filozof C, Fernandez Pinilla MC, Fernandez-Cruz A. Smoking cessation and weight gain. *Obes Rev*.
- 2004;5(2):95-103.
41. Poulsen P, Vaag A, Kyvik K, et al. Genetic versus environmental aetiology of the metabolic
- syndrome among male and female twins. *Diabetologia*. 2001;44(5):537-43.
42. Monda KL, North KE, Hunt SC, et al. The genetics of obesity and the metabolic syndrome. *Endocr*
- Metab Immune Disord Drug Targets*. 2010;10(2):86-108.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
43. Kristiansson K, Perola M, Tikkanen E, et al. Genome-Wide Screen for Metabolic Syndrome Susceptibility Loci Reveals Strong Lipid Gene Contribution But No Evidence for Common Genetic Basis for Clustering of Metabolic Syndrome Traits. *Circulation: Cardiovascular Genetics*. 2012;5(2):242-49.
44. Joy T, Lahiry P, Pollex RL, et al. Genetics of metabolic syndrome. *Curr Diab Rep*. 2008;8(2):141-8.
45. Povel CM, Boer JM, Reiling E, et al. Genetic variants and the metabolic syndrome: a systematic review. *Obes Rev*. 2011;12(11):952-67.
46. Lyssenko V, Sjögren M, Almgren P, et al. Genetic prediction of the metabolic syndrome. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2008;2(4):245-52.
47. Kim JY, Ahn SV, Yoon JH, et al. Prospective study of serum adiponectin and incident metabolic syndrome: the ARIRANG study. *Diabetes Care*. 2013;36(6):1547-53.
48. Juonala M, Saarikoski LA, Viikari JS, et al. A longitudinal analysis on associations of adiponectin levels with metabolic syndrome and carotid artery intima-media thickness. The Cardiovascular Risk in Young Finns Study. *Atherosclerosis*. 2011;217(1):234-9.
49. Barazzoni R, Silva V, Singer P. Clinical biomarkers in metabolic syndrome. *Nutr Clin Pract*. 2014;29(2):215-21.
50. Hajer GR, van der Graaf Y, Olijhoek JK, et al. Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome. *Heart*. 2007;93(2):216-20.
51. Esteghamati A, Hafezi-Nejad N, Zandieh A, et al. Homocysteine and metabolic syndrome: From clustering to additional utility in prediction of coronary heart disease. *Journal of Cardiology*. 0)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
√ <b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
√ <b>Introduction</b>		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
√ <b>Methods</b>		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses
√ <b>Results</b>		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

<b>√Discussion</b>		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
<b>√Other information</b>		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).